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Abstract 
 
Objectives: To assess the effects of radiation dose and volume parameters to the larynx by 
assessing the mucosal reactions with flexible laryngoscopy and its correlation with voice-
related quality of life using V-RQOL questionnaire, in patients undergoing Intensity-
modulated radiation therapy for non-laryngeal head and neck malignancies. Methods: DVH 
dose and volume parameters including Dmax, Dmean, V5 to V73.5 were obtained. Patients 
underwent flexible laryngoscopy prior to, during and at the completion of radiation therapy, 
and laryngeal oedema was graded as per RTOG grading criteria. The V-RQOL questionnaire 
was administered at same time points, and QOL scores including total, socioemotional and 
physical subdomains were calculated. Results: Among the total of 31 patients, two and six of 
them had grade 2 oedema midway during and at the end of radiation therapy respectively. 
Ten (32.3%), eight (25.8%) and ten (32.3%) patients had a V-RQOL total, socio-emotional 
and physical scores less than 75 at midway assessment respectively. But this increased to 17 
(54.8%), 15 (49.4%) and to (83.9%) at the end of radiation therapy respectively. There was a 
significant correlation of V65 with laryngeal oedema; and V60, V65 and V70 with the total V-
RQOL score at the end of RT, V5 to V70 with socioemotional V-RQOL and V65 with the 
physical domain of the V-RQOL score. OAR constraints for larynx in IMRT could be V60 
<1% for grade 2 laryngeal oedema, and V65< 1% for V-RQOL to be less than 75 at the end 
of radiation therapy. Conclusion: OAR constraints for larynx in IMRT could be V60 <1% for 
grade 2 laryngeal oedema, and V65< 1% for V-RQOL to be less than 75 at the end of 
radiation therapy. Keywords: IMRT, voice-related quality of life, laryngeal oedema, V-RQOL 
questionnaire. 
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Introduction 
 
The patients with non-laryngeal head and neck carcinomas receive radiation therapy 
to the neck for treating the draining lymph nodal groups, which were involved 
clinically or as elective neck irradiation. The radiation dose required for tumour 
control would cause acute and late normal tissue effects in the form of dermatitis, 
mucositis, xerostomia, dysphonia and dysphagia. Radiation received to the larynx 
during irradiation of other head and neck primary tumours and/or elective neck 
irradiation results in oedema of the larynx. This affects the voice quality of the patient 
to a varying extent. This limits the patients’ quality of life and handicaps them in 
personal and professional spheres of life. There are different interview based and self-
administered questionnaires to assess the voice-related quality of life. 
Intensity-modulated radiation therapy (IMRT) has a definite advantage in head and 
neck cancers, in that the treatment can be accurately delivered because it results in 
relative sparing of normal structures such as parotid glands, and also organ motion is 
virtually absent with proper immobilization. There is limited data about the dose and 
volume limits of radiation to the larynx. With the notable exception of the parotid 
glands, the available clinical data do not allow an accurate definition of dose-volume 
objectives for most other OARs in the head-and-neck region. If the values of dose-
volume parameters to keep the incidence of laryngeal oedema to the minimum in 
IMRT of non-laryngeal head and neck malignancies can be defined, it can be utilized 
to maximally improve the voice quality in these patients. 
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Aims 
 
To assess the effects of radiation dose and volume to the larynx and quality of life in 
intensity modulated radiation therapy for non-laryngeal head and neck malignancies. 
 
 
Objectives 
 
Primary objective 
 
 To assess the effects of radiation dose and volume parameters to the larynx in patients 
undergoing Intensity modulated radiation Therapy for non-laryngeal head and neck 
malignancies by assessing the mucosal reactions with flexible laryngoscopy. 
         
Secondary objective 
 
 To assess the Quality of Life in patients undergoing Intensity Modulated Radiation 
therapy for non-laryngeal head and neck cancers using Voice-related quality of life (V-
RQOL) questionnaire and its relation with dose-volume parameters. 
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Literature review 
 
Head and neck malignancies 
 
Incidence and prevalence 
 
World scenario 
Head and neck cancer account for more than 550,000 cases and 380,000 deaths 
annually worldwide(1). In the United States, head and neck cancer accounts for 3 per 
cent of malignancies, with approximately 63,000 Americans developing head and 
neck cancer annually and 13,000 dying from the disease(2). In Europe, there were 
approximately 250,000 cases (an estimated 4 per cent of the cancer incidence) and 
63,500 deaths in 2012 (3).  
Male to female ratio ranges from 2:1 to 4:1. About 90% of all head and neck cancers 
are squamous cell carcinomas (HNSCC). HNSCC is the sixth leading cancer by 
incidence worldwide. Most HNSCCs arise in the epithelial lining of the oral cavity, 
oropharynx, larynx and hypopharynx. The incidence of malignancies of oral cavity, 
nasopharynx, oropharynx and larynx are 2.1%, 0.6%, 1.0% and 1.1% respectively as 
per the GLOBOCAN 2012 data for both sexes worldwide(4). Oral cavity cancers are 
the most common with oral tongue. Laryngeal cancer is the second most common 
Head and Neck Cancer with >1, 59, 000 new cases and 90,000 cancer deaths 
worldwide and it forms 2% of all cancers. 
 
Indian scenario 
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The head and neck squamous cell carcinomas account for one-third of cancers in our  
country. According to the Indian Council of Medical Research (ICMR), 0.2 to 0.25 million  
patients are diagnosed each year with head and neck cancers (5). The prevalence rates of head 
and neck cancers in India as reported by GLOBOCAN 2012 is very high. The prevalence 
rates of Lip & Oral cavity cancers, larynx, nasopharynx, other pharynx were 12.6%, 6.8%, 
1.1% and 7% respectively. This shows the high burden of head and neck cancers in India with 
5-year prevalence rates of nearly 27 per cent. 
 
Oral cavity: 
India has a much higher incidence of oral cavity cancer as compared to the western world. 
Age-standardized incidence rates in India is 7.5 per 100,000 population, but in Europe and 
USA, it is 4.6 and 3.8 per 100,000 respectively. Among the different sites, oral cavity cancer 
is the leading cause of cancer-related mortality in India, especially in men accounting for 
22.9%. As the subsite of the oral cavity, the oral tongue is the most common site in the rest of 
the world, but in India gingivobuccal complex is most common. (6). The males of 
Ahmedabad urban showed highest Age-Adjusted Rate (AAR) for mouth cancer (12.9) 
followed by Bhopal (9.9). For females, however, Bengaluru showed the highest AAR (6.5) 
followed by Kamrup urban district (5.8). 
 
Laryngeal cancer: 
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In males, East Khasi Hills District (11.1) had the highest Age-adjusted rate (AAR) in 
laryngeal cancers followed by Aizawl District (9.5) and Kamrup urban District, in 
Assam (8.2). 
 
Hypopharynx: 
In males, the AARs of hypopharyngeal cancers in East Khasi Hills District of 
Meghalaya was 21.5 and the state of Meghalaya as a whole was 17.4, which were 
higher followed by Aizawl District (15.4) of Mizoram. In females, Kamrup Urban 
District (Assam) showed the highest AAR (3.6) followed by Cachar District (Assam) 
(2.6). 
 
Table 1: Number of registered cancer cases in different cancer registries throughout 
India and the proportion of Head and Neck Cancers 
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Aetiology 
 
The most commonly linked risk factors to head and neck cancer are tobacco use, alcohol 
consumption, human papillomavirus (HPV) infection (for oropharyngeal cancer), and 
Epstein-Barr virus (EBV) infection (for nasopharyngeal cancer). This, in long-term, leads to 
the development of head and neck malignancies. The relative prevalence of these risk factors 
in different parts of the world explains the differences in the incidence of subsites of head and 
neck cancer in each area.  
 
Tobacco 
Tobacco use may be either in the smoked form or smokeless tobacco. The smoked tobacco 
may be in the form of cigarettes, cigars, pipes, bidis and hukkas. There are other forms of 
smokeless tobacco which have high consumption rates and form a major causative agent for 
head and neck malignancies. Commonly used tobacco products are chewing tobacco, moist 
snuff, pan or betel quid and gutkha. All these tobacco products have been found to have 
carcinogens and have been implicated in the causation of a large number of malignancies 
including head and neck malignancies. The relative risk (RR) in current tobacco users was 
6.5. The RR increased with the duration of smoking and gradually declined after smoking 
cessation, with no excess risk at 20 years. (7) 
Smokeless tobacco (both chewing tobacco and snuff) is associated with an increased risk of 
cancer of the oral cavity and pharynx. In never smokers, the use of smokeless tobacco 
products appears to be associated with an increased risk of head and neck cancer, particularly 
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for malignancies arising in the oral cavity. In never smokers using snuff, the risk of head and 
neck cancer was significantly increased compared with never users of snuff (odds ratio [OR] 
1.71, 95% CI 1.08-2.70, and OR for oral cavity cancers 3.01, 95% CI 1.63-5.55). The 
association with chewing tobacco was weaker and was statistically significant only for 
cancers of the oral cavity (OR 1.81, 95% CI 1.04-3.17). (8) 
 
Alcohol 
Alcohol consumption independently increases the risk of cancer in the upper aerodigestive 
tract, although it is often difficult to separate the effects of smoking and alcohol. (9) The RR 
of developing head and neck cancer due to alcohol appears to be dose-dependent. As an 
example, one study reported a five- to six-fold increased risk for head and neck cancer with 
alcohol intake greater than 50 g/day versus less than 10 g/day (one drink contains 
approximately 12 g of alcohol). (10) 
According to the WHO Global Status Report on Alcohol 2004(11), worldwide consumption 
of alcohol in 2010 was equal to 6.2 litres of pure alcohol consumed per person aged 15 years 
or older, which translates into 13.5 grams of pure alcohol per day. Worldwide 61.7% of the 
population aged 15 years or older (15+) had not drunk alcohol in the past 12 months i.e. were 
abstainers. In 2012, about 3.3 million deaths, or 5.9% of all global deaths, were attributable to 
alcohol consumption. 
As per the 2003 National Household Survey of Alcohol and Drug Abuse(12)in India of 
40,697 males aged between 12 to 60 years revealed that 74.1% of the sampled population was 
lifetime abstainers. 21.4% were reported to be current users of alcohol (used in the last 30 
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days)(13). Prevalence was approximately 23% among adults and the older age group (30 
years and above) and 4.2% among adolescents and young adults (10 to 29 years). Alcohol 
intake and tobacco smoking appear to have an interactive and multiplicative effect on the risk 
of developing head and neck cancer. (14) 
 
Betel nut chewing 
Betel nut chewing, which is widespread in certain regions of Asia, is an independent risk 
factor for the development of squamous cell head and neck cancer. The effects appear to be 
synergistic with tobacco and alcohol. (15) 
Preparation of betel quid which is chewed varies between places. In Southcentral Asia, betel 
quid is chewed along with tobacco mostly, whereas in other parts of Asia it is used without 
tobacco. The contents are areca nut (Areca catechu), along with slaked lime (calcium oxide 
and calcium hydroxide), which is wrapped in the leaf of Piper betel plant with other 
condiments and spices. 
A meta-analysis of all studies about the impact of betel nut chewing with or without tobacco 
on head and neck and oesophagal cancers in Asia reported that the relative risk of oral cavity 
and oropharyngeal cancers for betel quid with tobacco was 77.4 and without tobacco was 
2.56. 
 
Viral infections 
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Multiple types of viral infections have been associated with an increased risk of head and 
neck cancer, including particularly EBV, HPV, and human immunodeficiency virus (HIV). 
 
EBV association with nasopharyngeal cancers 
EBV has been well established as an etiologic factor in the pathogenesis of nasopharyngeal 
carcinoma(16).  
Epithelial infection of EBV may not be the initiating event in the pathogenesis of 
nasopharyngeal cancer. There are a few genetic changes which predispose to subsequent 
EBV infection like 3p and 9p deletions, and possibly environmental factors such as dietary 
consumption of smoked or salted fish. Stable EBV infection of epithelial cells requires an 
altered, undifferentiated cellular environment and that cyclin D1 overexpression (a 
consequence of p16 deletion on chromosome 9p and amplification of the cyclin D1 locus on 
chromosome 11q) facilitates persistent EBV infection of immortalized nasopharyngeal 
epithelial cells.  
Nasopharyngeal carcinoma cells express a specific subgroup of EBV-latent proteins, 
including EBNA-1 and two integral membrane proteins, LMP-1 and LMP-2, which may be 
used for confirmation of EBV. Alternatively, EBV DNA detection by PCR can be done. 
Smoking may be involved in the pathogenesis of nasopharyngeal carcinoma by causing EBV 
reactivation(17). 
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HPV-association with Oropharyngeal cancers(18) 
Despite the prevalence of smoking and in turn the overall incidence of head and neck cancers 
decreasing over the past two decades, the oropharyngeal cancer incidence was steadily 
increasing. This is particularly in the base of the tongue and tonsil subsites, where the 
incidence has increased by 2-3% annually during 1973-2001, and then by 5.22% annually 
from 2000 to 2004 in the USA. Similar trends are observed in other countries also. 
Approximately 50 per cent of oropharyngeal cancers were attributable to HPV. The timing 
between exposure to HPV and the development of oropharyngeal cancer probably exceeds 10 
years(19). 
HPV-positive patients are mostly younger with a median age of 54 years at diagnosis, with 
less history of use of tobacco and alcohol and higher socioeconomic status and education. In 
the USA, HPV is less prevalent in blacks as compared to the white population. Also, HPV-
positive tumours present typically with early T stage (T1-T2) and higher N stage (usually 
cystic and multilevel), lesser incidence of metastases, and with a distinct pattern than HPV 
negative tumours. They have distinct histological features, such as moderate/poor tumour 
differentiation and non-keratinizing or basaloid pathology. The HPV-positive oropharyngeal 
cancer had a 28% reduction in the risk of death and a 49% reduction in the risk of disease 
recurrence and has a better prognosis than HPV negative oropharyngeal cancers. (20) 
The most common high-risk HPV types are HPV16, HPV18, HPV31, HPV33 and HPV35. 
These types are estimated to cause about 5% of the cancer burden worldwide, which includes 
about 25%–60% of head and neck cancers among other sites. 
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Figure (i): HPV induced carcinogenesis 
Most of the low-grade HPV infections are cleared off by the body. The high-grade infections 
or the long lasting ones result in viral DNA integration into the host genome. It starts with the 
destruction of E2 gene and higher expression of the oncogenes E6 and E7 in basal layer 
leading to a disruptive viral infection and incomplete viral life cycle and causes disruption of 
the cell cycle checkpoints. 
Degradation of pRB protein by E7 will result in activation of elongation factor (E2F) and 
subsequent transcription of S phase genes. The uncontrolled transcription of S phase genes 
also leads to the expression of p16INK4a (encoded by CDKN2A), a CDK inhibitor, as a 
negative feedback loop, which is also used as surrogate marker for HPV infections. E6 binds 
to E3 ubiquitin ligases and results in degradation of TP53, which leads to cell cycle 
deregulation, due to loss of p21 function (CDK inhibitor) and loss of TP53 mediated 
apoptosis. 
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P16 is used as a surrogate marker of HPV infection. It is tested using immunohistochemistry 
and has good sensitivity for HPV positive oropharyngeal cancers. (21) 
 
Fig(ii): p16 by IHC (A) Case 1 shows brown nuclear and cytoplasmic staining 
indicating p16 positive status; (B) Case 2 shows no staining indicating p16 negative 
status. 40X magnification. (IHC - immunohistochemistry) 
 
HPV association with Non-oropharyngeal cancers: 
A systematic review and meta-analysis identified 148 studies, including 12,163 cases of 
squamous cell carcinoma of the head and neck. The HPV prevalence rates in oropharyngeal, 
oral cavity, and laryngeal cancers were 45.8, 24.2, and 22.1 per cent, respectively, and the 
prevalence rates of HPV-16 positivity were 40.6, 14.9, and 13.4 per cent, respectively(22). 
The presence of HPV-16 in the oral cavity has been associated with the subsequent 
development of oropharyngeal carcinoma. 
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HIV 
HPV related oropharyngeal carcinoma, EBV-related SCC and LEC of salivary gland 
origin, NPC are non-AIDS defining malignancies. With the use of highly active 
antiretroviral therapy (HAART) an increased survival of these patients, there is an 
increased prevalence of these AIDS-associated malignancies. This is also attributed to 
increased CD4 counts due to HAART and direct oncogenic effect of HIV. There is an 
approximately two- to threefold increase in the incidence of SCC of the head and neck 
in patients infected with HIV; other histologic types of cancer may also be 
increased(23,24). 
Occupational exposure: 
The agents with a potential relationship with head and neck cancer include the dry 
cleaning agent perchloroethylene, asbestos, pesticides, man-made mineral vitreous 
fibres (MMMF), polycyclic aromatic hydrocarbons. Textile workers, woodworkers, 
manufacturers of mustard gas, plastic and rubber products, naphthalene refiners, 
ethanol, sulfuric acid mist, leather and paint workers, automobile mechanics, 
construction workers (cement), farmers, and metal workers are at increased risk for 
head and neck cancers. Formaldehyde was classified as a carcinogen in 2004 because 
of its association with nasopharyngeal cancer and possibly cancers of the nasal cavity 
and paranasal sinuses. SCCs of the larynx and the base of the tongue have also been 
associated with exposure to Agent Orange. (25) 
Radiation 
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Prior irradiation for either malignant or benign disease has been linked to thyroid 
cancer, salivary gland tumours, SCCs, and sarcomas. Although this relationship 
appears to be real, there is a long latency period, and the overall risk is low. (25) 
Occupational exposure to radiation has also been linked to carcinogenesis. INWORKS 
study(26) showed a linear increase in the rate of cancer with increasing radiation 
exposure. The excessive relative rate per Gy for death was 0.51. The estimated rate of 
mortality from all cancers excluding leukaemia increased with cumulative dose by 
48% per Gy (90% confidence interval 20% to 79%), lagged by 10 years.  
 
Diet  
Frequent consumption of salted fish, smoked or preserved meats that contain high 
levels of added nitrites have an 80% increased risk of developing nasopharyngeal 
carcinoma(27).  
 
Genetic factors  
Patients with Fanconi anaemia are at high risk for developing a malignancy, including 
SCC of the head and neck, myelodysplastic syndrome, and acute myelocytic 
leukaemia. Head and neck cancers in these patients tend to arise at an earlier age and 
in the absence of other risk factors (tobacco, alcohol)(28). 3% of Fanconi anaemia 
patients had head and neck malignancy(29). The management of patients with head 
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and neck cancer arising with Fanconi anaemia is complicated by the significant 
increase in susceptibility to complications of radiation therapy(30). 
Anatomical sites and subsites of head and Neck cancer 
The major sites include (1) the oral cavity, (2) the oropharynx, (3) the hypopharynx, 
(4) the larynx, (5) the nasopharynx, and (6) the nose and paranasal sinuses. These sites 
and the sub-sites are depicted in Figure-1. 
 
 
Figure (iii): Depicting various sites and sub-sites of Head and Neck epithelial 
malignancies. 
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The sites and subsites as listed in AJCC 8th edition is as follows: 
Lip 
1. External upper lip (vermilion border) 
2. External lower lip (vermilion border) 
3. Commissures 
Oral Cavity  
1. Buccal mucosa 
a. Mucosa of upper and lower lips 
b. Cheek mucosa 
c. Retromolar areas 
d. Buccoalveolar sulci, upper and lower (vestibule of mouth) 
2. Upper alveolus and gingiva (upper gum) 
3. Lower alveolus and gingiva (lower gum) 
4. Hard palate 
5. Tongue 
a. Dorsal surface and lateral borders anterior to vallate papillae (anterior two thirds) 
b. Inferior (ventral) surface 
6. Floor of mouth 
Oropharynx 
1. Anterior wall (glossoepiglottic area) 
a. Base of the tongue (posterior to the vallate papillae or posterior third) 
b. Vallecula  
2. Lateral wall 
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a. Tonsil 
b. Tonsillar fossa and tonsillar (faucial) pillars 
c. Glossotonsillar sulci (tonsillar pillars) 
3. Posterior wall 
4. Superior wall 
a. The inferior surface of soft palate 
b. Uvula 
Nasopharynx 
1. Posterosuperior wall: extends from the level of the junction of the hard and soft 
palates to the base of the skull 
2. Lateral wall: including the fossa of Rosenmüller 
3. Inferior wall: consists of the superior surface of the soft palate 
Histology 
The WHO working group on Head and Neck tumours published classification for 
tumours of head and Neck in 2003. The most common type is the malignant epithelial 
tumours which include Squamous cell carcinoma, Verrucous carcinoma, Basaloid 
squamous cell carcinoma, Papillary squamous cell carcinoma, Spindle cell carcinoma, 
Acantholytic squamous cell carcinoma, Adenosquamous carcinoma, Lymphoepithelial 
carcinoma and Giant cell carcinoma. Salivary gland-type tumours include 
mucoepidermoid carcinoma and adenoid cystic carcinoma, and adenomas which are 
pleomorphic adenoma and oncocytic papillary cystadenoma. Other classes of tumours 
include neuroendocrine tumours, soft tissue and bone sarcomas, lymphomas, mucosal 
malignant melanomas and other benign tumours. 
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Nasopharyngeal carcinoma has been classified by WHO classification of Head and 
Neck tumours published in 2017 as follows: 
1. Nasopharyngeal carcinoma 
a. Non-keratinizing squamous cell carcinoma 
(i) Undifferentiated 
(ii) Differentiated 
b. Keratinizing squamous cell carcinoma 
(i) Well-differentiated carcinoma 
(ii) Moderately differentiated carcinoma 
(iii) Poorly differentiated carcinoma 
c. Basaloid squamous cell carcinoma 
2. Nasopharyngeal papillary adenocarcinoma 
3. Salivary gland-type tumours. 
 
Diagnostic evaluation 
The evaluation includes a detailed history and physical examination including a 
thorough head and neck examination. Clinical examination of the primary involves 
assessing the type of lesion (proliferative, infiltrative), extent and involvement of 
underlying structures. Examination under anaesthesia (EUA) is also performed for 
deep lesions that are difficult to assess. 
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FNAC/ biopsy 
Fine needle aspiration cytology (FNAC) is done when there are palpable neck nodes. 
The sensitivity is 85 to 90%. Non-diagnostic aspirations and poor yield occur when 
the nodes are cystic, more common in HPV positive oropharyngeal cancers. 
Nasopharyngolaryngoscopy 
Nasopharyngolaryngoscopy is done for diagnosis of nasopharyngeal, laryngeal and 
hypopharyngeal tumours. The size and location of the lesion can be described, and 
biopsy from the lesion can be taken for histological diagnosis. 
In Direct Laryngoscopy, a flexible fibre optic laryngoscope is inserted through the 
mouth or nose to evaluate the larynx, for mobility of the vocal cords or any mucosal 
lesions. In Indirect Laryngoscopy, an IDL mirror is used to view an inverted image of 
the larynx and the surrounding structures. 
 
Ultrasound 
Metastatic lymph nodes in head and neck cancers are site-specific and depend on the 
location of the primary tumours most often. USG helps in the identification of 
metastatic nodes with the help of certain identifying features. Size of the node helps to 
distinguish between reactive and malignant node. Generally, malignant nodes tend to 
be larger than the reactive nodes. In head and neck malignancy nodes more than 
10mm are considered to be significant according to size criteria. Nodes with rounded 
shape with the short axis to long axis diameter more than 0.5 are more likely to be 
malignant. Eccentric cortical hypertrophy due to focal tumour infiltration is also a 
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diagnostic feature of malignant neck nodes. The borders of malignant nodes are sharp, 
and they are usually hypoechoic and may have calcifications. Although matting is a 
typical feature of tuberculosis, it is also seen in advanced malignancies. 
CT and MRI 
Computerized tomography is the mainstay for imaging head and neck cancers. Most 
centres acquire axial CT images from skull base to diaphragm. (31)The advantage of 
CT is its spatial resolution, but at the cost of radiation exposure, and is excellent in 
bony detail such as mandibular or skull base involvement. The disadvantage of CT is 
insufficient soft tissue characterization for imaging the tongue primary and preferably 
is to be used when MRI not available. If CT is done then contrast-enhanced CT is 
mandatory; performed after injection of 50-80 ml low osmolar non-ionic iodine-
containing contrast; CT images to be viewed at high contrast settings. Multidetector 
CT with multiplanar reformations (at least 16 slice scanner)is preferred. Images of 
both soft tissue and bone window are preferable to be viewed axially and with coronal 
reformation to assess extrinsic muscles, mandible and neurovascular bundle. CT is the 
most specific modality for mandibular erosion with high positive predictive value. 
However mandibular invasion is infrequent in tongue cancers, seen in< 10%, i.e. in 
advanced cancers or bulky tumours reaching or involving floor of the mouth. 
 
MRI T1-weighted ‘anatomical’ images have an excellent spatial resolution, while T2-
weighted images preferentially highlight oedema and therefore pathology. STIR 
images suppress the surrounding fat and have the capability of enhancing oedema or 
the pathology as a more bright signal than the conventional T2 images. 
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MRI is the imaging method of choice due to superior soft tissue characterization and 
when performed optimally provides accurate information regarding staging and 
tumour thickness. A tumour to normal tongue contrast is maximum on contrast-
enhanced T1W sequences that help to achieve accurate staging. MRI is very sensitive 
for mandibular erosion and has high negative predictive value, but can overestimate 
cortical erosion due to chemical shift artefacts. Nodal status is studied with a 
combination of T2W, STIR and post-gadolinium sequences but adding diffusion-
weighted imaging (if available) can increase the accuracy of the nodal status 
evaluation. The features of nodes that can be appreciated in MRI are: 
1. Number & size of abnormal nodes 
2. Level of abnormal nodes 
3. Ipsilateral, contralateral or bilateral 
4. Presence of necrosis 
5. Evidence of extra-capsular spread 
6. Invasion of adjacent structures and vessels (circumferential contact with ICA/CCA) 
 
There are two meta-analyses showing the equivalence of ultrasound, CT and MRI in 
the detection of nodal metastases. Few studies exist comparing CT and MRI for 
imaging the oral cavity with emphasis on tongue cancers. MRI is favoured over CT 
for T staging (better soft tissue delineation) particularly for tongue and floor of mouth 
squamous cancers while CT and MRI were comparable for N staging. 
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PET CT 
PET CT, performed with 18- fluorodeoxyglucose as the tracer is most commonly 
used.  
(1) The upfront indication is in the evaluation of a neck node with unknown 
primary. 
(2) It can be used for staging head and neck cancers at diagnosis i.e. in evaluating 
distant metastases in stage III & IV tongue cancers particularly with large 
nodes in the lower neck. It can depict the extent of nodal involvement in the N+ 
neck but has no role in the evaluation of the N0 neck. 
(3) PET also has a role in post RT setting to distinguish between recurrence and 
post RT changes or necrosis. 
(4) The role in following up patients after treatment is not yet recommended 
according to 2013, the Royal College of Radiologists’ evidence-based 
guidelines. (32) 
 
Staging of head and neck cancer 
The staging of Head and Neck cancers follow the TN staging 8th edition(33)published 
by the American Joint Committee on Cancer (AJCC). Three categories comprise the 
system: T—the characteristics of tumour at the primary site (this may be based on 
size, location, or both); N—the degree of regional lymph node involvement; and M—
the absence or presence of distant metastases. The specific TNM status of each patient 
is then tabulated to give a numerical status of Stage I, II, III, or IV. Specific 
subdivisions may exist for each stage and may be denoted with a, b, or c status. T4a 
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disease indicates moderately advanced disease and is specific by subsite, but is still 
considered resectable. T4b disease is very advanced disease with findings— such as 
carotid artery encasement, prevertebral involvement, and skull base involvement—
that previously determined the disease to be unresectable. In general, the early-stage 
disease is denoted as Stage I or II disease, and advanced stage disease as Stage III or 
IV disease. Of importance is that any positive metastatic disease to the neck will 
classify the disease as advanced, except in select nasopharynx and thyroid cancers. 
T4a disease is staged as IVa. T4b disease is staged as IVb, and any distant metastasis 
is staged as IVc. 
 
Detailed staging of carcinomas of the oral cavity, oropharynx and nasopharynx is as 
follows: 
Oral cavity tumours 
T staging 
T1- Tumour 2 cm or less in greatest dimension and 5 mm or less depth of invasion 
T2- Tumour 2 cm or less in greatest dimension and more than 5 mm but no more 
than10 mm depth of invasion or Tumour more than 2 cm but not more than 4 cm in 
greatest dimension and depth of invasion no more than 10 mm 
T3- Tumour more than 4 cm in greatest dimension or more than 10 mm depth of 
invasion 
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T4a (Lip) Tumour invades through cortical bone, inferior alveolar nerve, floor of 
mouth, or skin (of the chin or the nose) 
T4a (Oral cavity) Tumour invades through the cortical bone of the mandible or 
maxillary sinus or invades the skin of the face 
N staging 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension 
without extranodal extension 
N2 Metastasis described as: 
N2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not more 
than 6 cm in greatest dimension without extranodal extension 
N2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in 
greatest dimension, without extranodal extension 
N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in 
greatest dimension, without extranodal extension 
N3a Metastasis in a lymph node more than 6 cm in greatest dimension without 
extranodal extension 
N3b Metastasis in a single or multiple lymph nodes with clinical extranodal extension 
(The presence of skin involvement or soft tissue invasion with deep fixation/tethering 
underlying muscle or adjacent structures or clinical signs of nerve involvement is 
classified as a clinical extranodal extension. Midline nodes are considered ipsilateral 
nodes) 
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M – Distant Metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
 
pN – Regional Lymph Nodes 
Histological examination of a selective neck dissection specimen will ordinarily 
include10 or more lymph nodes. Histological examination of a radical or modified 
radical neck dissection specimen will ordinarily include 15 or more lymph nodes. 
pNX Regional lymph nodes cannot be assessed 
pN0 No regional lymph node metastasis 
pN1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension 
without extranodal extension 
pN2 Metastasis described as: 
pN2a Metastasis in a single ipsilateral lymph node, less than 3 cm in greatest 
dimension with an extranodal extension or, more than 3 cm but not more than 
6 cm in greatest dimension without extranodal extension 
pN2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in 
greatest dimension, without extranodal extension 
pN2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in 
greatest dimension, without extranodal extension 
pN3a Metastasis in a lymph node more than 6 cm in greatest dimension without 
extranodal extension 
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pN3b Metastasis in a lymph node more than 3 cm in greatest dimension with an 
extranodal extension or, multiple ipsilateral, or any contralateral or bilateral node(s) 
with extranodal extension 
 
Clinical stage group T N M   Pathological stage group 
0 Tis N0 M0   0 
I T1 N0 M0   I 
II T2 N0 M0   II 
III 
T3 
T1-3 
N0 
N1 
M0 
M0 
  III 
IVA 
T4a 
T1-4a 
N0-1 
N2 
M0 
  IVA 
M0 
IVB 
T4b 
Any T 
Any N 
N3 
M0 
  IVB 
M0 
IVC Any T Any N M1   IVC 
 
 
Oropharynx p16 negative or p16 status unknown: 
T staging 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
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Tis Carcinoma in situ 
T1 Tumour 2 cm or less in greatest dimension 
T2 Tumour more than 2 cm but not more than 4 cm in greatest dimension 
T3 Tumour more than 4 cm in greatest dimension or extension to lingual surface of 
epiglottis 
T4a Tumour invades any of the following: larynx,* deep/extrinsic muscle of 
tongue(genioglossus, hyoglossus, palatoglossus, and styloglossus), medial pterygoid, 
hard palate, or mandible. 
T4b Tumour invades any of the following: lateral pterygoid muscle, pterygoid plates, 
lateral nasopharynx, skull base; or encases carotid artery 
Note: * Mucosal extension to lingual surface of epiglottis from primary tumours of the 
base of the tongue and vallecula does not constitute an invasion of the larynx. 
N staging 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension 
without extranodal extension 
N2 Metastasis described as: 
N2a Metastasis in a single ipsilateral lymph node more than 3 cm but not more than6 
cm in greatest dimension without extranodal extension 
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N2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in 
greatest dimension, without extranodal extension 
N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in 
greatest dimension, without extranodal extension 
N3a Metastasis in a lymph node more than 6 cm in greatest dimension without 
extranodal extension 
N3b Metastasis in a single or multiple lymph nodes with clinical extranodal 
extension* 
Pathological Nodal staging 
Oropharynx p 16 Negative 
pNX Regional lymph nodes cannot be assessed 
pN0 No regional lymph node metastasis 
pN1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension 
without extranodal extension 
pN2 Metastasis described as: 
pN2a Metastasis in a single ipsilateral lymph node, less than 3 cm in greatest 
dimension with an extranodal extension or more than 3 cm but not more than 
6 cm in greatest dimension without extranodal extension 
pN2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in 
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greatest dimension, without extranodal extension 
pN2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in 
greatest dimension, without extranodal extension 
pN3a Metastasis in a lymph node more than 6 cm in greatest dimension without 
extranodal extension 
pN3b Metastasis in a lymph node more than 3 cm in greatest dimension with an 
extranodal extension or, multiple ipsilateral, or any contralateral or bilateral node(s) 
with extranodal extension 
Clinical stage group T N M   Pathological stage group 
0 Tis N0 M0   0 
I T1 N0 M0   I 
II T2 N0 M0   II 
III 
T3 
T1-3 
N0 
N1 
M0 
M0 
  III 
IVA 
T4a 
T1-4a 
N0-1 
N2 
M0 
  IVA 
M0 
IVB 
T4b 
Any T 
Any N 
N3 
M0 
  IVB 
M0 
IVC Any T Any N M1   IVC 
 
Oropharynx – p16‐Positive Tumours: 
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Tumours that have positive p16 immunohistochemistry overexpression. 
T1 Tumour 2 cm or less in greatest dimension 
T2 Tumour more than 2 cm but not more than 4 cm in greatest dimension 
T3 Tumour more than 4 cm in greatest dimension or extension to lingual surface of 
epiglottis 
T4 Tumour invades any of the following: larynx*, the deep/extrinsic muscle of 
tongue(genioglossus, hyoglossus, palatoglossus, and styloglossus), medial pterygoid, 
hard palate, mandible*, lateral pterygoid muscle, pterygoid plates, lateral 
nasopharynx, skull base; or encases carotid artery 
Note: * Mucosal extension to lingual surface of epiglottis from primary tumours of the 
base of the tongue and vallecula does not constitute an invasion of the larynx. 
Oropharynx p‐16 Positive 
Clinical 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Unilateral metastasis, in lymph node(s), all 6 cm or less in greatest dimension 
N2 Contralateral or bilateral metastasis in lymph node(s), all 6 cm or less in greatest 
dimension 
N3 Metastasis in lymph node(s) greater than 6 cm in dimension 
Clinical group staging 
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Clinical stage group T N M 
0 Tis N0 M0 
I T1 N0/N1 M0 
 T2 N0/N1 M0 
II 
T1-2 
T3 
N2 
N0-2 
M0 
M0 
III 
T1-3 
T4 
N3 
Any N 
M0 
M0 
IV Any T Any N M1 
    
Pathological group staging 
Pathological stage 
group 
T N M 
0 Tis N0 M0 
I T1-2 N0-1 M0 
II T1-2 N2 M0 
T3 N0-1 M0 
III T3-4 N2 M0 
IV Any T Any N M1 
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Nasopharynx 
T staging 
T1 Tumour confined to the nasopharynx, or extends to the oropharynx and/or nasal 
cavity without parapharyngeal involvement 
T2 Tumour with extension to parapharyngeal space and/or infiltration of the medial 
pterygoid, lateral pterygoid, and/or prevertebral muscles 
T3 Tumour invades bony structures of skull base cervical vertebra, pterygoid 
structures, and/or paranasal sinuses 
T4 Tumour with intracranial extension and/or involvement of cranial nerves, 
hypopharynx, orbit, parotid gland and/or infiltration beyond the lateral surface of the 
lateral pterygoid muscle. 
 
N staging 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Unilateral metastasis, in cervical lymph node(s), and/or unilateral or bilateral 
metastasis in retropharyngeal lymph nodes, 6 cm or less in greatest dimension, 
above the caudal border of the cricoid cartilage 
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N2 Bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, 
above the caudal border of the cricoid cartilage 
N3 Metastasis in cervical lymph node(s) greater than 6 cm in dimension and/or 
extension below the caudal border of the cricoid cartilage 
Stage grouping: 
Clinical stage group T N M    
0 Tis N0 M0    
I T1 N0 M0    
II T1 N1 M0    
 T2 N0/1 M0    
III 
T1-2 
T3 
N2 
N0-2 
M0 
M0 
 
  
IVA T4 N0-2 M0    
IVB Any T N3 M0    
IVC Any T Any N M1    
 
Kadish staging for esthesioneuroblastoma(34) 
A- In situ or limited to the septum, floor, lateral wall, meatus, nasal concha, and 
vestibule with or without bony invasion  
B- Origin in the paranasal sinuses or further extension into the paranasal sinuses and 
nasoethmoidal complex  
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C- Cases with extension into the skull base, palate, cribriform plate, medial wall or 
floor of the orbit, pterygoid plates, nasopharynx, skin, dura, and brain  
D- With nodal disease or metastatic disease  
 
TNM staging for Nasal cavity and paranasal sinuses 
T – Primary Tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
Maxillary Sinus 
T1 Tumour limited to the mucosa with no erosion or destruction of bone 
T2 Tumour causing bone erosion or destruction, including extension into the hard 
palate and/or middle nasal meatus, except extension to posterior wall of maxillary 
sinus and pterygoid plates 
T3 Tumour invades any of the following: bone of posterior wall of maxillary sinus, 
subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses 
T4a Tumour invades any of the following: anterior orbital contents, skin of cheek, 
pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses T4b 
Tumour invades any  of the following: orbital apex, dura, brain, middle cranial fossa, 
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cranial nerves other than  maxillary division of trigeminal nerve (V2), nasopharynx, or 
clivus 
Nasal Cavity and Ethmoid Sinus 
T1 Tumour restricted to one subsite of the nasal cavity or ethmoid sinus, with or 
without bony invasion 
T2 Tumour involves two subsites in a single site or extends to involve an adjacent site 
within the nasoethmoidal complex, with or without bony invasion 
T3 Tumour extends to invade the medial wall or floor of the orbit, maxillary sinus, 
palate, or cribriform plate 
T4a Tumour invades any of the following: anterior orbital contents, the skin of nose or 
cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or 
frontal sinuses 
T4b Tumour invades any of the following: orbital apex, dura, brain, middle cranial 
fossa, cranial nerves other than V2, nasopharynx, or clivus 
N – Regional Lymph Nodes 
N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension 
without extranodal extension 
N2 Metastasis described as: 
N2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 
cm in greatest dimension without extranodal extension 
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N2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest 
dimension, without extranodal extension 
N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in 
greatest dimension, without extranodal extension 
N3a Metastasis in a lymph node more than 6 cm in greatest dimension without 
extranodal extension 
N3b Metastasis in a single or multiple lymph nodes with clinical extranodal 
extension* 
M – Distant Metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
 
pTNM Pathological Classification 
The pT categories correspond to the clinical T categories.  
pN – Regional Lymph Nodes 
Histological examination of a selective neck dissection specimen will ordinarily 
include10 or more lymph nodes. Histological examination of a radical or modified 
radical neck dissection specimen will ordinarily include 15 or more lymph nodes. 
pNX Regional lymph nodes cannot be assessed 
pN0 No regional lymph node metastasis 
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pN1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension 
without extranodal extension 
pN2 Metastasis described as: 
pN2a Metastasis in a single ipsilateral lymph node, less than 3 cm in greatest 
dimension with an extranodal extension or, more than 3 cm but not more than 6 cm in 
greatest dimension without extranodal extension 
pN2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest 
dimension, without extranodal extension 
pN2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in 
greatest dimension, without extranodal extension 
pN3a Metastasis in a lymph node more than 6 cm in greatest dimension without 
extranodal extension 
pN3b Metastasis in a lymph node more than 3 cm in greatest dimension with an 
extranodal extension or multiple ipsilateral, or any contralateral or bilateral node(s) 
with extranodal extension 
Stage grouping is same as for Oropharynx p16 negative. 
 
Prognosis 
The different subsites in head and neck cancers have a different prognosis, and it also 
differs with stage, histology and anatomical location of the tumour. It is mostly the T 
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stage of the disease and the presence or absence of nodal metastasis which serve as 
important prognostic factors related to survival.  
 
Advanced T stage is associated with worse local control and overall survival. Also, 
advanced N stage predicts the increased risk of distant metastasis and worse survival. 
Presence of distant metastasis (M1) at the time of presentation indicates a poor 
prognosis. The presences of bone erosion, cranial nerve palsy or lower nodal level are 
all poor prognostic factors. Histology wise, Non-keratinizing and undifferentiated 
carcinomas are more radiosensitive and have a better prognosis than keratinizing 
squamous cell carcinoma. 
HPV positive oropharyngeal tumours have a better prognosis as compared to their 
negative counterparts. Hence there are a series of de-escalation trials which are 
ongoing. These trials are based on three main strategies (1) Exploring cetuximab as an 
alternative to cisplatin when given concurrently with radiation. (2)Reduction of 
radiation dose when given in combination with chemotherapy as primary treatment 
(guided by induction chemotherapy response) and (3) Reduction of adjuvant 
chemotherapy or radiotherapy dose following primary treatment with surgery (guided 
by histopathological features in the resected specimen). 
 
Management overview of head and neck cancers 
Generally, management for early stages I and II is single modality treatment with surgical 
resection and dissection of the draining lymph nodal groups or radical radiation therapy. 
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Stages III and locally advanced stage IV requires multimodality treatment including radical 
chemoradiation therapy or surgery followed by postoperative radiation therapy +/- 
chemotherapy. 
Surgery 
When different modalities are available, the modality that gives maximum chance of cure 
should be used. When different modalities have similar results, a modality that gives a better 
quality of life, with organ / function preservation is preferred. 
Surgery is preferred over radiotherapy as a single modality in (1) sites where surgery is not 
morbid (cosmetically and functionally), (2) lesions involving or close to bone - to prevent 
radionecrosis, (3) young patients – possibility of a subsequent second primary and (4) 
presence of submucous fibrosis (SMF). Reconstruction options with good cosmesis should be 
planned prior to surgery. 
Radiotherapy is preferred over surgery as a single modality, where (1) severe impairment of 
function / cosmesis with surgery, e.g. base tongue, glottis, (2) surgery is technically difficult 
with high morbidity and poor results e.g. nasopharyngeal carcinoma, (3) patient refuses 
surgery and (4) high risk of surgery. 
 
Postoperative radiation therapy without chemotherapy 
Indications: 
Primary: 
(1) Large primary – T3/T4 
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(2) Deep infiltrative tumour 
(3) A high-grade tumour 
(4) Lymphovascular and perineural invasion 
(5) Level IV/ V nodes in the oral cavity and oropharyngeal tumours 
Lymph nodes: 
(1) Bulky nodal disease N2/N3 
(2) Extranodal extension 
(3) Multiple level involvement 
(4) Multiple nodes 
 
Postoperative chemoradiotherapy 
Indications: 
(1) Positive or close margin after curative resection 
(2) Nodes with perinodal extension 
 
Brachytherapy 
Indications: 
(1) Accessible lesions 
(2) Small (preferable < 3 cm) tumours 
(3) Lesions away from the bone 
(4) N0 nodal status 
(5) Superficial lesions 
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The dose for radical brachytherapy: 
T1-2 N0: Radical Brachytherapy: 60-70Gy low dose rate Iridium (192Ir) or 48Gy in 12 
fractions (4 Gy twice daily) over 6 days with fractionated high dose rate. 
T1-3 N0-1: 
External RT 56 -60Gy in 28-30 fractions over 6wks followed by a boost with 
brachytherapy Low dose rate 192Iridium: 15-20 Gy or High Dose rate: 14Gy in 4 
fractions over 2 days (4-3-3-4 Gy) 
 
Organ preservation 
“Organ preservation” means to maintain an organ in an unchanged condition or to 
avoid its loss, whereas “function preservation” means that the function is preserved 
whether the organ is totally or partially preserved. Traditionally the surgery for 
advanced laryngeal, oro-hypopharyngeal cancers was always mutilating with loss of 
function. Organ preservation involves the use of multimodality treatment including 
radiation therapy, chemotherapy, biologicals and function-preserving surgery to help 
maintain the functional status of the organ.  
 
Chemotherapy 
Chemotherapy has a role in concurrent, neoadjuvant setting in locally advanced 
tumours or as palliative chemotherapy in metastatic tumours. 
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Cisplatin is the drug of choice for use concurrently with radiation therapy. Trials with 
concurrent chemotherapy Cisplatin showed significant benefit in head and neck 
cancers. The MACH-NC meta-analysis showed the benefit of adding concurrent 
chemotherapy to radiation therapy in head and neck cancers and results showed an 
improvement in overall survival rates at 5 years with the addition of concurrent 
chemotherapy. 
Neoadjuvant chemotherapy downsizes atumour that further helps in surgical resection 
with adequate margins or for better delivery of radiation therapy. The TAX 323 and 
324 trials show that in locally advanced unresectable head and cancers, neoadjuvant 
chemotherapy with Docetaxel, Cisplatin and 5 Fluorouracil, had long-term survival 
benefit in patients with unresectable disease. 
Biologic therapy 
Squamous cell carcinomas of the head and neck that overexpresses EGFR tends to 
have poor prognosis. Cetuximab is a monoclonal antibody that selectively targets 
EGFR receptor.Boner et al have shown that concurrent cetuximab with radical 
radiation therapy for locally advanced head and neck cancer improves locoregional 
control and reduces mortality without increasing common toxic side effects. 
Concurrent cetuximab is used for patients who cannot tolerate concurrent 
chemotherapy in view of poor performance status. 
Nimotuzumab is another anti-EGFR monoclonal antibody, which has been proven to 
be safe to use concurrently with radiation therapy. Tyrosine kinase inhibitors like 
Gefitinib and Erlotinib can be used in the palliative setting for metastatic tumours. 
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Adverse effects of treatment 
With advances in radiation therapy technology and multimodality treatment methods 
by addition of concurrent chemotherapy, multiple trials showed improvement in 
survival of patients with advanced head and neck cancer. The adverse effects of 
treatment would be of much significance in patients with increased survival and 
longer follow up. 
 
The common side effects that were observed with head and neck radiation therapy 
included: 
a. Xerostomia 
b. Mucositis 
c. Candidiasis 
d. Dysguesia 
e. Dental caries 
f. Osteoradionecrosis 
g. Trismus  
h. Oral Pain  
i. Dermatitis, soft tissue fibrosis 
j. Dysphagia 
k. Dysphonia 
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Radiation therapy techniques 
Conventional RT 
In conventional radiation therapy, patients were planned with 2-dimensional 
conventional methods of planning in which X-rays were taken to define the field 
borders. The field borders are placed depending on the anatomical extent of a tumour 
and the nodal spread of the disease. In the conventional planning methods, it is 
difficult to reduce the dose to the adjacent normal structures, without compromising 
the dose to the primary tumour. The radiation therapy beams deliver the same dose 
throughout to the primary tumour and to the adjacent normal structures. Customized 
blocks may be used to decrease the radiation dose to the normal tissue. However, the 
process of making customized blocks is very cumbersome and even with their use; the 
normal tissue still receives a very high dose. Thus, the therapeutic index for such a 
planning technique is very small with very high rates of complications due to 
increased radiation dose to normal tissue.  
 
Conformal RT 
It was the use of CT in radiation planning that led to innovations in planning 
techniques which included contouring of the tumour and the normal structures in each 
of the CT axial slices and delivering radiation more conformally to the tumour and 
areas at risk by avoiding the organs at risk. This was made possible by shaping the 
radiation beam with the use of multileaf collimators (MLCs). This comprised the 
3dimensional conformal radiation therapy or 3DCRT. 
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Even though in 1982, the concept of modulating the intensity of radiation beam was 
proposed by Brahme, it was not until the early years of the 21st century that this came 
into clinical practice as Intensity-modulated radiation therapy or IMRT. 
About Intensity modulated radiation Therapy (IMRT) 
 
IMRT is an advanced form of three-dimensional conformal radiotherapy. The 
introduction of CT into radiation oncology in the 1980s enabled treatment planning 
based on three-dimensional anatomical information of the tumour and surrounding 
healthy tissues, thus facilitating the establishment of three-dimensional conformal 
radiotherapy (3D-CRT). The key features of 3D-CRT treatment planning include 
beam’s eye view (BEV) design of treatment fields and plan evaluation. BEV allowed 
for finding a beam direction that could irradiate the tumour without the beam passing 
through nearby critical organs. Dose-volume histograms (DVHs) and isodose 
distributions became essential tools for plan evaluation. Together with the progress in 
3D image processing, the 3D volume information from CT also enabled accurate dose 
calculation using the convolution-superposition method, allowing the inhomogeneous 
distribution of tissues to be more accurately handled. (36) 
Whereas 3D-CRT exploits field shape conformation to improve target dose 
conformality, the organs at risk (OARs) located in the groove region of concave target 
volumes cannot be saved from the target dose. 
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Fig (iv) Comparison of the principle of 3D-CRT (A) and IMRT (B) with illustrations 
of forward vs. inverse planning. Considering the dose calculation problem of 
radiation therapy in terms of the concept of causality, while the causes are beam 
parameters including energy, direction, size, and intensities, the effects are dose 
distributions. 
In conventional 3D-CRT, the irradiation field shape coincides with the shape of the 
target according to the incidence direction of the irradiation beam, while in IMRT, the 
beam intensity is modulated according to the arrangement of the target and 
surrounding organs. The intensities of the rays that pass through OARs are reduced, 
while the intensities of the rays go primarily through the target volume are increased. 
The inhomogeneity caused by the ‘intentionally non-uniform intensity’ of a beam is 
compensated for by beams from other directions. Physically, a feature of the IMRT 
technique is to enhance control over the 3D dose distribution through the 
superposition of a large number of independent segmented fields, either from a 
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number of fixed directions or from directions distributed on one or more arcs. By this 
method of adding intensity modulation to geometric shaping, the IMRT dose 
distribution can be rendered concave, as opposed to the convex-shaped coverage 
accomplished with 3D-CRT, where geometric conformal shaping of a uniform 
intensity beam is performed. Therefore, IMRT can enable dose reduction to OARs 
located within a concave area of the planning target volume (PTV). 
It is of particular value for target volumes with concave or complex shapes with close 
proximity to radiosensitive normal structures. It has two key additional features 
compared to conformal radiotherapy: (a) non-uniform intensity of the radiation beams 
and (b) computerized inverse planning(37). The major salivary glands(38), the mucosa 
of the pharynx or of the oral cavity, the larynx(39), the constrictor muscles(40), the 
mandible(41), and the inner and middle ears(42) are examples of structures that can be 
partially spared when clinically feasible, due to the dose conformality afforded by 
IMRT. 
DVH and Dose-volume metrics 
A histogram may be plotted according to the usual mathematical definition, as 
the accumulated volume of those elements receiving a dose in a specified dose 
interval against a set of equispaced dose intervals. This is referred to as a differential 
dose-volume histogram. 
A more useful technique is to, however, plot the data as the volume receiving a dose 
greater than or equal to a given dose against that dose over the expected dose range. 
These plots are actually cumulative dose-volume frequency distributions. These 
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cumulative DVHs are more commonly used for plan evaluation. The lack of spatial 
information is a major limitation of DVHs. 
The data from DVH can be expressed in terms of dose received to a defined volume of 
the structure, or as a percentage of volume receiving a defined dose.  
 
ADVH metric is a character string which has three mandatory elements in the 
following order: 
* 1st letter is either "D" or "V": "D" if the requested value is a dose, "V" if it is a 
volume. 
* 2nd element (number): If the first letter is "D", this gives the volume for which the 
dose value of the cumulative DVH should be reported. If the first letter is "V", this 
gives the dose for which the volume value of the cumulative DVH should be reported. 
* 3rd element (measurement unit): The measurement unit for the 2nd element of the 
metric. Absolute volumes are indicated by "CC" for cm3, relative volumes by "%". 
Absolute doses are indicated by "Gy" for Gray or "cGy" for centigray, relative doses 
by "%". 
For Example:  
D33%: Dose received by 33% of the volume of the defined structure 
 D2cc: Dose received by 2cc of the volume of the defined structure 
V45Gy: Volume of the defined structure which receives at least 45Gy. 
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Larynx as an OAR and Constraints in literature for larynx 
Voice is important in speech and communication for two reasons: (1) Vocal delivery can help 
us engage and interest the audience. (2) Vocal delivery helps ensure that our ideas are 
communicated clearly. The different components of speech delivery are the rate, volume, 
pitch, articulation, pronunciation, and fluency. 
The vocal cords are the structures in larynx or glottis which are responsible for voice 
production. Oedema to the vocal cords during radiation therapy and later can have an impact 
on the quality of the voice, and in future can cause social handicap. This explains the 
relevance that the larynx has as an important organ at risk during the radiation therapy of 
head and neck cancers. 
Organs at risk or critical normal structures are tissues that if irradiated could suffer significant 
morbidity and thus influence the treatment planning and the dose prescription. From multiple 
clinical studies, the critical doses at which significant damage that can occur to an OAR can 
be deduced. Care can be taken not to cross these dose and volume constraints during radiation 
planning in order to maintain an acceptable quality of life for the patient. Conformal radiation 
therapy with IMRT helps to further reduce the dose to these organs at risk. 
The dose constraints for larynx used in RTOG 0922 was to keep the Mean Dose< 40 Gy or 
as low as possible. To reduce the incidence of severe laryngeal oedema, Dmean should be 
less than 43.5 Gy(39).  Equivalent uniform dose to larynx should be less than 30 to 35 
Gy(43) for grade 2 laryngeal oedema. When Dmean was less than 20 Gy, only 25% of 
patients had worse voice quality 6 months after radiation therapy(44). 
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Larynx contouring 
There are three methods available in the literature for contouring of laryngeal structures. 
While two of them describes contouring larynx entirely as a single structure, the third 
describes steps for contouring sub-site-wise and cartilages separately. 
1. Freedman et al 
2. A standardized method for laryngeal contouring by Choi et al 
3. DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and 
TROG consensus guidelines 
 
1. Guide for contouring larynx by Freedman published in Practical Radiation 
Oncology(45) 
This describes step by step guideline for contouring larynx based on the method used 
in RTOG 1016 trial.  
Step one: Identify the most inferior edge of the hyoid bone and begin contouring on 
the next slice inferiorly. 
Step two: The anterior boundary of the larynx contour is the inner surface of the 
thyroid cartilage. In the superior portion of the contour, the posterior boundary of the 
larynx is the lateral surfaces of the aryepiglottic folds and the posterior surface of the 
mucosa covering the arytenoids. Do not include the pyriform sinus in the larynx 
65 
 
contour. In the inferior portion of the contour, the posterior boundary of the larynx is 
the posterior surface of the cricoid cartilage.  
Step three: The most inferior extent of the larynx contour is the last image where the 
cricoid cartilage is seen as a complete ring. 
2. The standardized method by Choi published in Radiation Oncology(46) 
The thyroid, arytenoid and cricoid cartilages are contoured first. The aryepiglottic 
folds and false cords are contoured as a single structure as they are difficult to be 
identified separately by imaging, than by direct visualization.  
The epiglottis is contoured separately as suprahyoid part and infrahyoid part and 
combined together to form Epiglottis. Epiglottis, arytenoids, and the anteromedial 
wall of the aryepiglottic folds and false vocal folds are combined together to form the 
Supraglottis OAR. The postero-lateral wall of the aryepiglottic folds forms the medial 
wall of the pyriform sinuses and is part of the hypopharynx.  
The larynx OAR is created by combining the supraglottic larynx, glottic larynx, 
subglottic larynx, thyroid cartilage, and cricoid cartilage contours. 
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Fig (v): Landmarks for Contouring of larynx as per Freedman et al. Do not include 
pyriform sinus and air in the laryngeal contour. 
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3. DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG 
Oncology and TROG consensus guidelines(47) 
 
EORTC describes contouring of larynx separately as Supraglottic larynx, glottic area 
and arytenoids. 
The supraglottic larynx is delineated according to Christiansen et al. (48). Anatomic 
borders are as listed below: 
Cranial: Tip of the epiglottis 
Caudal: the Cranial edge of arytenoid cartilages 
Anterior: Hyoid bone, pre-epiglottic space, thyroid cartilage 
Posterior: Inferior PCM, pharyngeal lumen 
Lateral: Thyroid cartilage 
Medial: Pharyngeal lumen 
The glottic area is contoured as including the vocal cords and paraglottic fat. Air 
should be excluded from the contour. Borders are as below: 
Cranial: the cranial edge of arytenoid cartilages 
Caudal: the Caudal edge of anterior part of the thyroid cartilage. 
Posterior: Cricoid, anterior border arytenoids. 
The arytenoids (or arytenoids cartilage) is defined as a separate structure. The base 
(caudal edge) of each arytenoid is broad for articulation with the cricoid cartilage. The 
apex (cranial edge) is pointed. 
68 
 
 
Figure (vi): Axial CT slices of neck region: Showing delineation of the supraglottic 
larynx (A) glottic area (B) cricopharyngeal inlet muscle (C) and cervical oesophagus 
(D). Other organs at risks visible are the submandibular glands (1), pharyngeal 
constrictor muscles (2), carotid arteries (3), brachial plexus (4), spinal cord (5), 
arytenoids (6) and thyroid (7). 
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Grading systems for laryngeal oedema 
Radiation therapy induced laryngeal oedema is common and expected side effect. The 
grade of larynx oedema can be scored as per the RTOG scale, CTCAE v5.0 and 
Chandler’s classification. 
RTOG grading of Laryngeal oedema(49) 
RTOG grading is as follows: 0, no edema; 1, slight edema; 2, moderate edema; 3, 
severe edema; and 4, necrosis. The grade 1 and 2 oedema is defined as “slight” and 
“moderate” oedema, which poses a certain amount of uncertainty. Grade 1 oedema 
corresponds to minimal thickening of the epiglottis, aryepiglottic folds, arytenoids and 
false cords. Grade 2 is a more diffuse and evident oedema, although still without 
significant to symptomatic airway obstruction. Grade 3 is oedema causing airway 
compromise and grade 4 is with necrosis. 
CT-CAE v5.0 grading of Laryngeal oedema(50) 
1- Asymptomatic; clinical or diagnostic observations only; intervention not 
indicated 
2- Symptomatic; medical intervention indicated (e.g., dexamethasone, 
epinephrine, antihistamines) 
3- Stridor; respiratory distress; hospitalization indicated 
4- Life-threatening airway compromise; urgent intervention indicated (e.g., 
tracheotomy or intubation) 
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5- Death 
 
 
Fig (vii): Laryngoscopic view showing laryngeal oedema grades as per RTOG 
grading. Grades 0 (A, normal), 1 (B, mild), 2 (C, moderate), and 3 (D, severe) on 
RTOG classification. 
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Chandler’s Classification (49) 
Grade 1:   
Symptoms may include: Slight hoarseness and mucosal dryness 
Signs may include: Slight oedema and presence of telangiectasias. 
Grade 2:   
Symptoms may include: Moderate hoarseness and mucosal dryness. 
Signs may include: Moderate oedema and erythema, some TVC, hypomobility 
Grade 3:  
Symptoms may include: Severe hoarseness with dyspnea, moderate odynophagia and 
dysphagia 
Signs may include: Marked oedema, skin changes anterior neck, severely impaired or 
fixed unilateral TVC 
Grade 4:  
Symptoms may include: Respiratory distress, severe pain and odynophagia, weight 
loss, dehydration 
Signs may include Fistula, fetid odour, fever, severe skin changes anterior neck and 
laryngeal airway obstruction due to oedema. 
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Methods of assessing laryngeal toxicity in RT 
Objective methods 
The vocal function can be assessed quantitatively by three methods: 
(i) Videostroboscopy(51) for direct visualization to assess the supraglottic activity, 
vocal fold edge, amplitude, mucosal wave, phase asymmetry and glottis 
closure. 
(ii) Aerodynamic measurements of phonation time and  
(iii) Direct human observation by Direct laryngoscopy(52).  
(i) Videostroboscopy 
Laryngeal videostroboscopy (LVS) is the gold standard for evaluation of dysphonia 
and laryngeal function (53). LVS is an endoscopic tool that uses synchronized pulsed 
light at a frequency allowing the examiner to observe normal and pathologic vocal 
fold (VF) vibration and movement during phonation. A Strobe light is a flashing light 
that enables us to see a simulated picture of vocal fold vibrations in slow motion 
Stroboscopy is a special method, done as an office procedure, and is used to visualize 
vocal fold vibration by recording the video of the vocal cords while patient phonates. 
It uses a synchronized, flashing light passed through a flexible or rigid telescope. The 
flashes of light from the stroboscope are synchronized to the vocal fold vibration at a 
slightly slower speed, allowing the examiner to observe vocal fold vibration during 
sound production in what appears to be slow motion. The video which appears as in a 
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slower speed is actually an illusion because the speed of the vocal cord vibration is 
not changed by stroboscopy. 
Within the oncologic realm, LVS has most commonly been used for the diagnosis of 
early-stage glottic cancers but has also been employed as a metric of posttreatment 
voice. LVS offers improved diagnostic sensitivity over non-stroboscopic video 
laryngoscopy as it permits evaluation of functional changes in VF biomechanics and 
vibration. LVS can be used in tandem with validated perceptual voice assessments in 
order to correlate dysphonia with specific physiologic findings. To date, there is 
limited experience using LVS to assess the impact of definitive RT upon functional 
voice outcomes. (54) Marciscano et al(55) has used videostroboscopy for assessment 
of voice quality in patients with early glottic cancers post radiotherapy on follow up. 
 
Fig (viii) A rigid video stroboscope 
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(ix) Flexible videostroboscopy being performed on a patient 
(ii) Aerodynamic measurements 
Abnormal acoustic and aerodynamic measures are attributed to impairment of vocal 
fold vibration, as observed stroboscopically, with incomplete closure and reduced 
mucosal wave, as well as observed ventricular activity, the latter indicative of 
hyperfunction. (56) 
Electroglottographic (EGG) analyses of voice have revealed superior voice outcomes 
after primary chemoradiotherapy compared with patients with total laryngectomy and 
transesophageal puncture (TEP), with improvement over a 12-month period in the 
75 
 
chemoradiotherapy group (57). In postradiotherapy nasopharyngeal cancer patients, 
EGG analysis of vocal fold vibratory behaviour revealed higher speech quotient, a 
ratio of glottic opening time to closing time, and lower open quotient, an indication of 
longer closed phase relative to open phase in the cycle in these patients as compared 
with healthy controls. Both of these measures reflect increased vocal tension or 
resistance. These authors also found lower signal-to-noise ratios, indicative of voice 
abnormality. Others have found abnormal perturbation scores and abnormal 
perceptual ratings in patients treated with radio/chemoradiotherapy to the larynx.  
Abnormal measures of jitter, shimmer, harmonics-to-noise ratio, and fundamental 
frequency (i.e., increase in fundamental frequency) have been seen in irradiated 
laryngeal cancer patients as well (58). 
(iii) Direct Laryngoscopy(59) 
Laryngoscopy can be performed either indirectly by an indirect laryngoscope or 
directly by an angled telescope or with fibreoptic laryngoscopy. 
The traditional indirect laryngoscopy relies on a single hand-held mirror to reflect the 
structures of the larynx to sight. 
 Laryngoscopy by angled telescope allows a direct view of these structures also. 
Though both these techniques may be less expensive and easier to use initially, 
fiberoptic nasopharyngoscopy provides clearer visualization and better access to 
nasopharyngeal anatomy. 
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Fibre-optic flexible laryngoscope was initially developed in the 1930s by a medical 
student named Heinrich Lamm, followed by further innovations from Hopkins and 
Storz. It was in 1963, that a medically functional fiberoptic scope with higher 
resolution, lighting, suction, and instrument ports was designed by Hirschowitz. 
Current fiberoptic nasopharyngoscopes are lighted, are flexible with 2-way 
articulation, provide inline viewing with photo and video capabilities, and can have a 
distal diameter as small as 2 mm. 
 
Fig (x): Flexible laryngoscope 
Subjective methods 
Voice problems after radiotherapy may be attributed to observable dryness of the 
laryngeal mucosa, muscle atrophy, fibrosis, hyperaemia, and erythema. There are 
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various validated questionnaires(60,61) which are available for subjective assessment 
of the voice and speech related quality of life.  
(i)EORTC QLQC30/H&N35  
EORTC designed a modular instrument designed to bridge the roles of disease-
specific and global QOL scales. EORTC-QLQ-C30 was the core questionnaire 
(version 3.0). This consisted of 30 questions which were organized into 5 subdomains: 
physical (5), role (2), cognitive (2), emotional (4), and social (2). The global QOL 
assessment was done with H&N-35, which had 35 questions arranged into 7 domains. 
(ii)The Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N) 
FACT-G is a self-administered questionnaire which consists of 27 questions in 4 
domains - physical (7), social/family (7), emotional (6), and functional (7). The 38 
item FACT-H&N also includes an 11-item head and neck cancer specific subscale. 
(iii) The Head and Neck Radiotherapy Questionnaire (HNRQ) 
This is a questionnaire developed for use in patients with advanced stage (III and IV) 
malignancies to measure the radiation-induced acute morbidity and quality-of-life. It 
is a 22-item interviewer-administered scale representing 6 dimensions (skin, throat, 
oral stomatitis, digestion, energy, psychosocial), with each item rated on a 7-point 
Likert scale and 3 to 4 items per dimension. Higher scores were indicative of better 
quality of life. 
(iv) Quality of Life Instrument for Head and Neck Cancer (QL-H&N) 
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This questionnaire focusses on the psychological factors and is quite short and 
sensitive with disease-specific questions. This is a self-administered questionnaire 
which consists of composite psychometric scales, with added disease-specific 
questions. The full questionnaire has not been published but is known to include 29 
items. The physical, social and psychological domains are scored individually, but 
there is no summary score. 
(v) Quality of Life Questionnaire for Advanced Head and Neck Cancer (QLQ) 
The QLQ was designed and used in a UK study to discriminate between patients with 
advanced head and neck cancer randomized to either radiation alone or surgery and 
radiation. It was piloted as a 19-item self-assessed questionnaire, with 15 questions 
rated on a 4-point Likert type scale, and 4 questions rated on a 5-point scale. Details of 
scoring and the handling of missing responses have not been published. 
(vi) Quality of Life - Radiation Therapy Instrument Head & Neck Module (QOL-
RTI/H&N) 
This was developed at the University of South Florida. The current QOL-RTI/H&N is 
a questionnaire with 39 items, self-administered. All questions use a 10-item Likert 
response scale. The general portion consists of 4 domains: functional (9 questions), 
emotional (7 questions), family and socioeconomic (6 questions) and general (3 
questions). The disease-specific module has 14 items. The QOL-RTI and Head and 
Neck module are scored separately. 
(vii) The University of Michigan Head and Neck Quality of Life (HNQOL) 
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This 21-item instrument was intended for the overall assessment of outcome for 
patients with head and neck cancer. It is an interviewer-administered questionnaire 
assessing four domains: pain (4), emotion (6), communication (4) and eating (6). Each 
item is rated on a 5-point Likert scale, and each domain generates a score of 0–100, 
with higher scores reflecting better QOL. In addition, a single item assesses “overall 
disturbance or bother” as a result of head and neck cancer. A summary score is not 
calculated. 
(viii) University of Washington Quality of life questionnaire (UW QOL) 
It is a self-administered instrument consisting of 12 questions: 9 disease-specific items 
(pain, chewing, swallowing, speech, shoulder disability, appearance, activity, 
recreation and employment), plus 3 general items measuring global health-related 
QOL, change in health-related QOL since diagnosis, and overall QOL. Each question 
has 3–6 response options, using a Likert-type scale. Each item is scored from 0–100, 
with higher scores indicating better QOL, resulting in a summary score of 0–900 for 
the disease-specific items. The general items are scored individually.  
The UW QOL is a short instrument best suited to patients undergoing surgery. 
Although a recent revision has added some issues of potential importance to 
radiotherapy patients (dry mouth, change in taste), it is probably not the questionnaire 
of choice for patients undergoing radiation therapy. 
Table (I) Comparing the Questionnaires of Disease-Specific Quality Of Life in 
Head and Neck Cancer 
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(ix)VOICE HANDICAP INDEX (VHI) 
The VHI was developed using a sample of patients from diverse clinical settings with 
voice disorders thus encompassing a broad range of pathologies. There are a total of 
85 items and they are grouped into three: functional (25 items), emotional (31 items), 
and physical (29 items). It was ensured that this scale had both content and face 
validity. 
Construct validity was not fully evaluated in this study, although the relationship 
between patient self-perceived severity and VHI scores was determined to be 
moderately strong.  There are no comparable scales to cross-validate construct validity 
for the VHI. 
 
(x) VOICE RELATED QUALITY OF LIFE QUESTIONNAIRE (V-RQOL) 
The V-RQOL questionnaire was developed by Hogikyan and Sethuraman(62) at the 
University of Michigan. V-RQOL is a self-administered questionnaire that measures 
the subjective burden due to a voice disorder. It is short and has only 10 items with 2 
subscales: physical and social-emotional scales having 6 and 4 questions respectively. 
The overall V-RQOL score is assessed by the total scale. 
The ten questions are as follows: 
1. I have trouble speaking loudly or being heard in noisy situations. 
2. I run out of air and need to take frequent breaths while talking  
82 
 
3. I sometimes do not know what will come out when I begin speaking      
4. I am sometimes anxious or frustrated because of my  
5. I sometimes get depressed because of my voice 
6. I have trouble using the telephone (because of my voice) 
 7. I have trouble doing my job or practising my profession (because of my voice) 
8. I avoid going out usually (because of my voice) 
 9. I have to repeat myself to be understood 
10. I have become less outgoing (because of my voice) 
Of the above questions, Numbers 4, 5, 8 and 10 are to assess the socioemotional 
quality of life; and the rest six of them belong to the physical domain. Each question 
has a 5 point Likert scale. The scoring is done by first adding all the points together 
for total; and the scores of only the corresponding questions for the socioemotional 
and physical domains. The formula for calculating the V-RQOL score is as follows: 
Socioemotional V-RQOL score= 100-  
 
Physical V-RQOL score= 100-  
 
Total V-RQOL score= 100-  
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The detailed questionnaire and the method of scoring are attached in Appendix (III) 
and (IV). 
The V-RQOL questionnaire has been validated in India in a study conducted in Tata 
Memorial Hospital, Mumbai, in two regional languages of Hindi and Marathi. In this 
study by Deshpande et al (63), V-RQOL scores were higher in patients younger than 
50 years. Most of the patients (91%) received radiotherapy either preoperatively or 
postoperatively. Therefore the effect of radiotherapy on V-RQOL was not tested, 
though radiotherapy had shown a significant difference in other studies. 
There was no statistically significant difference in V-RQOL whether surgery was 
done per upfront or as salvage after failure of radiotherapy. Sex, site of a tumour, type 
of surgery (including the extent of resection, type of closure, neurectomy, and 
myotomy) did not have any effect on the V-RQOL scores. 
 
Correlation of DVH parameters with laryngeal oedema 
 
Sanguineti et al(39) conducted a retrospective study in 66 patients with head and 
neck squamous cell carcinomas with uninvolved larynx who had undergone IMRT 
and had at least 1 fibreoptic laryngoscopy at 2 years of follow up. The dose volume 
parameters Dmean and V20 to V70 was evaluated from each plan. V30 to V70 showed 
correlation with Grade ≥2 oedema. The Dmean when kept below 43.5 Gy, there was no 
grade 2 oedema. By multivariate analysis, the predictors of laryngeal oedema were 
mean larynx dose and N+ stage. 
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Rancati et al(64) performed a study on 48 patients with head and neck non-laryngeal 
carcinomas for finding the best-fit parameters of normal tissue complication 
probability (NTCP) models for laryngeal oedema after radiotherapy for head and neck 
cancer. Flexible laryngoscopy was performed at 15 months for assessing laryngeal 
oedema. Patients who underwent any major surgery other than tonsillectomy and neck 
dissection was excluded. All patients underwent either IMRT or 3DCRT.  2 NTCP 
models were used- Lyman model and Logit model. In the Lyman model, DVH was 
reduced to the effective volume by Kutcher-Burman method (LKB). In the Logit 
model, DVH was reduced to Equivalent Uniform Dose (EUD) (LOGEUD). 25 out of 
48 (52.1%) experienced G2–G3 oedema. 
This was conducted in the same patient population as that of Sanguineti et al (39) and 
showed a large volume effect for laryngeal oedema. This is consistent with the parallel 
architecture of the larynx for this endpoint. An EUD of < 35 to 40 Gy was expected to 
reduce the risk of laryngeal oedema > grade 2 and this should be the dose objective for 
EUD based optimization IMRT. 
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Fig (xi): Plot of the probability of larynx oedema for irradiation of whole, two thirds, 
and one-third of the larynx (Lyman equivalent uniform dose [LOGEUD] normal 
tissue complication probability [NTCP] model 
 
Fung et al(51) conducted a study in non-laryngeal head and neck cancer patients who 
completed radiation therapy at least 12 months prior and was on follow up. The RT 
was by conventional 3 fieldsisocentric technique and treated using a 4 MV linear 
accelerator or cobalt-60. Patients with primaries of Tonsil, Soft palate, Vallecula, 
submandibular gland or unknown primary were included in the study. Patients with 
early glottic tumours were taken as the control group. The larynx was assessed using 
videostroboscopy, acoustic measurements and aerodynamic measurements after 12 
months from completion of RT. The total RT dose delivered ranged from 60 to 74 Gy 
and the mean laryngeal dose was 50 Gy. Quality of life assessment was also done 
using VHI. All the patients were male and had a prior history of smoking. There was 
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increased supraglottic activity on videostroboscopy in the non-laryngeal group. 75% 
of the acoustic measures were worse in the non-laryngeal group including relative 
amplitude perturbation, amplitude perturbation quotient, normalized noise energy, 
pitch amplitude and spectral flatness ratio. 
A study on voice quality on 43 patients with laryngeal or hypopharyngeal 
malignancies undergoing chemoradiation as part of larynx preservation protocol was 
conducted by Carrara de-Angelis et al(57). Total radiation dose delivered was 70.4 
Gy. Radiation therapy was delivered by conventional planning methods. Voice was 
analysed perceptually by GRBAS scale by two independent observers and acoustically 
by 9 acoustic parameters. Perceptual analysis and acoustic analysis was done and 
showed normal results in 1 patient, mild dysphonia in 4 patients, moderate in 6 
patients and severe dysphonia in 4 patients. The voice abnormalities were mild to 
moderate and allowed unintelligible communication in the studied group of patients. 
A study from Korea by Bae et al(65), conducted in 127 patients with laryngeal and 
hypopharyngeal malignancies to assess the risk factors predictive of significant 
laryngeal oedema(SLE) by repeated flexible laryngoscopic examinations over a period 
of 2 years after completion of radiation therapy. The mean follow up was 35 months. 
Of these 127 patients, 2 (2%) underwent intensity-modulated radiotherapy (IMRT) 
and others underwent conventional external beam RT. The total prescribed dose Dmax 
<68 was correlated against various factors to find the association with significant 
laryngeal oedema. Significant laryngeal oedema was present in 44%. T classification 
was an independent predictor of significant laryngeal edema in multivariate analysis 
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(T1 vs. T2–4; odds ratio = 5.070, 95% confidence interval = 1.999–12.857; P = 
0.001). Univariate analyses showed that tumour location, T and N classifications, 
overall stage, pathologic differentiation, and chemotherapy were significantly 
predictive of significant laryngeal oedema (P < 0.05). There was a recurrence of the 
tumour in 27%. Tumor recurrence rate was higher (39% vs. 7%, P < 0.001) and 3-year 
overall survival rate lower (54% vs. 87%, P < 0.001) in those with significant 
laryngeal edema as compared to those without SLE. 
L. M. Dsouza Lawrence et al (66) conducted a study in 67 patients with non-
laryngeal Head and Neck cancers undergoing IMRT to elucidate the predictors of 
laryngeal oedema. Patients underwent planning CT and a repeat CT at 6 to 7 weeks 
after initiation of RT to assess the absolute and relative change in the volume of the 
larynx. Mean cumulative laryngeal dose was calculated for each of the patients and 
was correlated with factors including age, sex, alcohol and tobacco use, primary site 
and stage, N stage, prior neck surgery, neoadjuvant chemotherapy and weight loss 
during treatment.  
Mean (SD) initial and final volumes were 17.4 (3.7) and 20.0 (4.3) cc, respectively. 
The larynx increased in volume in all but 4 patients. The laryngeal volumes at 
planning were divided into tertiles. Mean (SD) per cent change from baseline was 
15.7% (13.1%); the first and second tertiles were 7.5% and 20.6%, respectively. 
Increasing laryngeal volume at planning was directly correlated with, and the only 
predictor of those in the lower tertile. Increasing age was directly correlated with a 
swelling of the larynx in those in the higher tertile. 
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 In a study by Marcisano et al(55), fifteen patients with early glottic cancer Tis-T2N0 
was included. The radiation therapy was by conventional methods for 7 patients and 
with IMRT for eight of them. Laryngeal Vidoestroboscopy (LVS) of the larynx prior 
to and after radiation therapy at 0 to 4 months (acute), 4 to 12 months (subacute) and 
>12 months (chronic) was performed. The grading was done according to six 
parameters: vocal fold (VF) vibration, VF mobility, erythema/ oedema, supraglottic 
compression, glottic closure, and secretions. Grade, roughness, breathiness, asthenia, 
strain (GRBAS) voice perceptual scale was graded along with the LVS score by an 
observer. The radiation parameters studied were dose per fraction, number of fractions 
and overall treatment time. There were significant improvements in ipsilateral VF 
motion (P = 0.03) and vibration (P = 0.001) and significant worsening in contralateral 
VF motion (P < 0.001) and vibration (P = 0.008) at >12 months post-RT. Glottic 
closure significantly worsened, most prominent >12 months post-RT (P = 0.01). 
Composite GRBAS scores were significantly improved across all post-RT intervals. 
These results demonstrated that Laryngeal videostroboscopy can detect meaningful 
changes in VF and glottic function and support its use for post-RT evaluation of 
glottic cancer patients. 
In a study by Dornfield et al (67), 27 patients with non-laryngeal head and neck 
carcinomas who underwent IMRT were studied. The total dose by IMRT was 66 to 70 
Gy and the anterior neck field was delivered using conventional 4 MV beam to 50 Gy. 
Radiation doses delivered to various points along the upper aerodigestive tract, 
including the base of tongue, lateral pharyngeal walls, and laryngeal structures 
including pre-epiglottic space, aryepiglottic folds, false cords, lateral pharyngeal walls 
89 
 
at the level of false cords and upper oesophageal sphincter were recorded. Higher 
doses delivered to the aryepiglottic folds, false vocal cords, and lateral pharyngeal 
walls near the false cords correlated with a more restrictive diet, and higher doses to 
the aryepiglottic folds correlated with greater weight loss (p < 0.05) 1 year after 
therapy. Point dose should be less than 68Gy. 
 
Correlation of DVH parameters with the voice-related quality of life 
 
Vainshtein et al(44) from the University of Michigan conducted a study on 91 
patients with stage III and IV oropharyngeal cancers, who underwent definitive 
chemoradiation with IMRT. The quality of life was assessed with the communication 
domain of HNQOL-C and speech questions in the UWQOL-S. The assessments were 
done prior to, and after radiation therapy till 24 months after completion of treatment. 
The radiation dose-volume parameters studied were Mean dose and V20 to V60. 
92% of patients were HPV positive. Median Dmean was 33.7 Gy. Mean glottic dose 
<20 Gy, 20 to 30 Gy, 30 to 40 Gy, 40 to 50 Gy and > 50 Gy was seen in 13, 24, 24, 11 
and 19 patients respectively. Voice quality decreased maximally at 1 month, with 68% 
and 41% of patients reporting worse HNQOL-C and UWQOL-S scores compared 
with before treatment, and improved thereafter, recovering to baseline by 12 months 
when assessed with HNQOL-C and  18 months by UWQOL-S. Of patients with mean 
glottis  dose <20 Gy, >20-30 Gy, >30-40 Gy, >40-50 Gy, and >50 Gy, 25%, 33%, 
59%, 50%, and 64% reported worse voice quality at 6 months compared with 
pretreatment (p<0.02), which persisted at 12 months in 10%, 32%, 25%, 30%, and 
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63% of patients, respectively (P<.011).Univariate analysis revelaed that Mean glottic 
dose, N stage, neck dissection, oral cavity dose and time since chemoradiation was 
associated with voice or speech worsening. At multivariate analysis Mean glottic dose 
alone was associated. 
In a study by Dornfield et al(67), mentioned above, QOL was assessed using HNCI 
QOL score before treatment and after 1 year. Better post-treatment speech Quality of 
life (QOL) scores were associated with lower doses delivered to structures within and 
surrounding the larynx. 
Ma et al(68) was a retrospective comparison of patients with early glottic cancers 
who underwent transoral laser surgery versus conventional radiation therapy in terms 
of long-term voice outcome assessed objectively with both central spectral index and 
GRBAS scoring by two blinded speech pathologists and subjectively with the help of 
a VHI-10 questionnaire. The group who received RT had better GRBAS by 1.38 
points and cepstral spectral index by 13.7 points (p<0.01). 
Fung et al(51)as mentioned above, also assessed the voice quality of life with Voice 
handicap index (VHI) in his study. Voice handicap was significantly greater in the 
nonlaryngeal group in all three domains (p<0.05). When compared with patients 
receiving small field RT for early glottic tumours, there is objective and subjective 
evidence of vocal dysfunction in patients treated with wide-field RT for nonlaryngeal 
tumours. 
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Fung(69)conducted yet another study in patients with advanced laryngeal cancers, 46 
of them with stage III and 51 with stage IV who underwent radical radiation therapy 
by a conventional method. After 1 cycle of induction chemotherapy with cisplatin 100 
mg/m2 and 5 fluorouracil 1000mg/m2 Day 1 to 5, Patients were further randomized 
based on the response. Those with less than 50% response underwent early salvage 
laryngectomy, and patients with 50% or better response underwent concurrent 
chemoradiation (72 Gy and cisplatin 100 mg/m2 on Days 1, 22, and 43), followed by 
two cycles of adjuvant chemotherapy (CDDP/5-FU). All patients 8 weeks after 
chemoradiation underwent direct laryngoscopy and biopsy, and if there was residual 
disease underwent salvage laryngectomy. The voice quality of life was assessed with 
the V-RQOL questionnaire and List performance status scale for head and neck cancer 
patients (PSS-HN). Patients with an intact larynx demonstrated significantly higher (p 
- 0.02) mean V-RQOL scores (80.3) than did laryngectomy patients (65.4). This 
finding was consistent in the social-emotional (p-0.007) and physical functioning 
domains (p -0.03). No differences in V-RQOL scores were found in comparisons 
between early and late salvage laryngectomy. Predictors of a higher (better) V-RQOL 
score assessed by multiple linear regression model was low T stage, organ 
preservation and longer duration since treatment. 
 
Ma et al(68)as mentioned above, also compared the voice quality of life between the 
TLM (Transoral Laser microexcision) and RT group. The mean V-RQOL scores for 
patients who had undergone radiotherapy (n=63), chemoradiotherapy (n=29), laser 
surgery (n=14), or total laryngectomy (n=27) as final treatment of laryngeal cancer 
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were 92.6, 92.9, 85.5, and 68.4, respectively; the mean VHI-10 scores were 2.87, 2.34, 
5.43, and 11.26, respectively. The VRQOL and VHI-10 questionnaires are important 
in judging the overall effectiveness of treatment options for laryngeal cancer. There 
was no significant difference in VHI-10 between RT and TLM groups. 
 
Oridate et al(70) conducted a study in 137 patients with laryngeal tumours who 
underwent TLM, RT, chemoradiation therapy and laser surgery who were followed up 
for a mean of 38 months. The radiation therapy was by conventional technique ≥60 
Gy, generally 65 Gy. The total dose of RT was compared against the QOL scores for 
each group. The mean scores were 92.6, 92.9, 85.5 and 68.4 for RT, chemoradiation, 
laser surgery and TML groups respectively. (70) 
Correlation of laryngeal oedema with QOL 
 
Fung et al (51)compared voice function between two groups of patients who received 
radical radiation therapy, quantitatively by videostroboscopy, aerodynamic 
measurements and acoustic analyses. VHI score was used for the assessment of voice 
quality of life. It was found that the non-laryngeal cancer patients who received “wide 
field” RT had significantly worse voice quality of life and fared worse in the 
quantitative measurements as well. Patients with laryngeal early-stage cancer who 
received “small field” RT was used as a control in the study as the aim of the study 
was to assess the voice quality with RT in the previously unaffected larynx. This was 
more intriguing that these patients who received a higher dose to larynx had better 
QOL on follow up than non-laryngeal patients. 
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Methods and materials 
 
Inclusion criteria: 
 
(1) Patients undergoing locoregional radical radiotherapy or chemoradiotherapy 
with IMRT for non-laryngeal head and neck malignancies. 
(2) No clinical symptoms or signs of laryngeal dysfunction. 
 
Exclusion criteria 
 
(1) Any tumour primarily involving the larynx or extending from other subsites. 
(2) Any history of benign laryngeal pathology or surgical interventions in neck or 
larynx. 
 
The patients who met the above-mentioned criteria underwent radiation treatment 
planning. Computerized Tomography 3mm cuts were taken from vertex to T4 level, 
with the patient in a supine treatment position, immobilized with a thermoplastic shell. 
The primary tumour volume (GTV p) and  involved  neck nodal levels (GTVn) were 
contoured. The clinical target volume and planning target volume was developed from 
the above. Brain, brainstem, spinal cord, eye, lens, cochlea, parotid gland, pharyngeal 
constrictors, lips, oral cavity, larynx, thyroid, heart, lungs, brachial plexus were 
contoured as critical organs. Brainstem, spinal cord, optic nerve and chiasm were also 
given margins to form corresponding PRVs (planning organ-at-risk volume) 
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The larynx contouring was done according to the protocol followed in RTOG 
1016(71), outlined by Freedman et al(45). The volume defined as larynx is from the 
tip of the epiglottis superiorly to the bottom of the cricoid inferiorly; the external 
cartilage framework is excluded from the laryngeal volume. 
Step one: Identify the most inferior edge of the hyoid bone and begin contouring on 
the next slice inferiorly. 
Step two: The anterior boundary of the larynx contour is the inner surface of the 
thyroid cartilage.  
In the superior portion of the contour, the posterior boundary of the larynx is taken as 
the lateral surfaces of the aryepiglottic folds and the posterior surface of the mucosa 
covering the arytenoids. The pyriform sinuses are not included in the larynx contour. 
In the inferior portion of the contour, the posterior boundary of the larynx is the 
the posterior surface of the cricoid cartilage. 
Step three: The most inferior extent of the larynx contour is the last image where 
the cricoid cartilage is seen as a complete ring. 
All patient received radiation therapy as clinically indicated by the IMRT plan. Some 
patients receive radiation therapy as SIB, whereas others received it in sequential 
phases. 
The radiation treatment of these patients was carried out according to the approved 
IMRT treatment plan after QA . 
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 Dose Volume histograms (DVH) were developed for each IMRT plan. The dose 
volume parameters including maximum dose (Dmax) and mean dose (Dmean) to the 
larynx, V5 (the volume of larynx receiving 5 Gy), V10, V15, V20, V25, V30, V35, V40, 
V45, V50, V55, V60, V65, V70and V73.5 was estimated from the DVH. The Dmax was 
calculated as point dose (Dmax) and Maximum dose received to 1cc (Dmax1cc) of the 
laryngeal volume and was measured in centigray (cGy). The volume parameters 
measured the volume of the larynx receiving that particular mentioned radiation dose 
in Gy and was expressed in percentages as a percentage of the total laryngeal volume.  
Laryngoscopy was performed at three time points: prior to initiation of radiation 
therapy, midway during radiation therapy (between 15th and 18th fraction) and at the 
end of radiation therapy. The dose volume parameters were compared with the 
laryngeal oedema grading assessed by flexible laryngoscopy at midway and at the end 
of radiation treatment. 
 The laryngeal oedema was graded according to the RTOG grading for laryngeal 
oedema as follows: 0, no oedema; 1, slight oedema; 2, moderate oedema; 3, severe 
oedema; and 4, necrosis.(72) Some degree of uncertainty is intrinsic to the subjectivity 
in the interpretation of ‘‘slight’’ and ‘‘moderate’’ in the RTOG scale. Grade 1 oedema 
would correspond to ‘‘minimal’’ thickening of the epiglottis, aryepiglottic folds, 
arytenoids, and false cords. Grade 2 is a more diffuse and evident oedema, although 
still without significant or symptomatic airway obstruction. The details are mentioned 
in Appendix-8. 
The patients were also assessed subjectively for the quality of life by administering a V-
RQOL questionnaire with 10 questions pertaining to voice and speech, each with a 5 point 
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Likert scale. The questionnaire was administered at the above mentioned time points as 
described for laryngoscopic assessment, i.e. prior to initiation of radiation therapy, midway 
during radiation therapy and at the end of radiation therapy. 
The V-RQOL total score and subdomains- socioemotional and physical were calculated using 
the formulas (Appendix IV). Those with a V-RQOL score >75 to 100 were classified as 
excellent, 51 to 75 as Good, 26 to 50 as OK and less than or equal to 25 as poor according to 
Deshpande et al(63).  
The scores were further grouped into excellent (more than 75) and non-excellent (less than or 
equal to 75) for the analytical purposes in this study. 
All patients undergoing IMRT for non-laryngeal head and neck malignancies 
↓ 
After the date of IRB approval of the study 
↓ 
Baseline Laryngoscopy (L1) 
V-RQOL questionnaire (Q1) 
↓ 
IMRT planning 
↓ 
Dose volume histograms created 
↓ 
At midway of IMRT 
Laryngoscopy (L2) 
97 
 
V-RQOL questionnaire (Q2) 
↓ 
Completion of IMRT 
↓ 
At completion, 
Laryngoscopy (L3) 
V-RQOL questionnaire (Q3) 
↓ 
Computing the dose volume parameters: 
Max dose, Mean Dose (Dmean) 
V20, V30, V40, V50, V60, V70 
↓ 
Analysis of the association of dose and volume with laryngeal oedema 
↓ 
Analysis of the association of laryngeal dose with Quality of life score. 
 
Statistical analysis: 
 
With reference to Sanguineti et al(39), the mean laryngeal dose was 48.4 ±10 Gy. By 
assuming a standard deviation of 3.5, absolute precision of 3, with 95% confidence 
interval, the required sample size for the study was calculated as 31. 
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Data was entered using EPIDATA software. Data was screened for outliers and 
extreme values using Box-Cox plot and histogram (for the shape of the distribution). 
Patient characteristics are expressed as mean and standard deviations or median and 
interquartile range (IQR) for continuous variables, frequencies, and percentages for 
categorical variables. The difference in baseline patient demographics and clinical 
characteristics were compared using Pearson chi-square tests for categorical variables 
and Student t tests or Mann-Whitney U test, when appropriate, for continuous 
variables. ROC analysis (Quality score) was done to find the best cutoff value of dose-
volume variables.  Statistical analyses were performed using SPSS 25 software. 
 
Results 
 
1. DEMOGRAPHIC DETAILS  
 
Age: There was a total of 31 patients out of which 19 (61.29%) were ≤50 years and 
the remaining 12 (38.70%) were >50 years of age. Mean age was 46.19± 12.8 years.  
Gender: 27 (87.1%) were males and 4 (12.9%) were females.  
Geographical distribution: It was comparable between different regions of India 
namely North Indian, North East Indian, South Indian and other groups (including 
those from Bangladesh) as 32.3%, 19.4%, 22.6% and 25.8% respectively. 
Habits: Nine (29%) patients gave a history of tobacco smoking. 11 (35.5%) of them 
had a history of using smokeless tobacco or pan chewing. None of them has a history 
of alcohol abuse. 
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Primary sites: Eighteen (58.1 %) of the patients had a nasopharyngeal primary. There 
were six (19.4%) patients with carcinoma oropharynx and three (9.7%) patients with 
sinonasal carcinoma. There was one (3.2%) patient each with oral cavity, carcinoma 
maxilla, olfactory neuroblastoma and others. 
Histology: The most common histological diagnoses of these patients were 
undifferentiated carcinoma (nine- 29%), poorly differentiated carcinoma (eight- 
25.8%) and poorly differentiated squamous cell carcinoma (five- 16.1%). 
TNM staging: Most of the tumours were T4a (thirteen- 41.9%), followed by T3 
(seven- 22.6%). There were four (12.9%) T2 tumours and five (16.1%) T1 tumours. 
Only one (3.2%) patient has T4b lesion.  
Most common nodal stage was N2a (eleven – 35.5%) followed by N0 (eight – 25.8 %) 
and N2b (five – 16.1%). There were three (9.7%) each patient with N1 and N2c 
stages, and one (3.2%) patient with the N3 stage.  
In total, there were 8 (25.8%) node negative and 23 (74.2%) node-positive patients. 
The most common overall stage was IVA (fifteen – 48.4%) followed by III (nine – 
29%) and IV B (six – 19.4%). Only one (3.2%) patient was stage II. 
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Fig (xii) showing the distribution of primary sites of malignancy among the patients. 
 
Fig (xiii): Distribution of different histologies reported among the patients  
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Fig (xiv): Stage-wise distribution among the patients 
Clinical Symptoms: Four (12.9%) patients had dysphagia as their presenting 
symptom, whereas nine (29%) had a nasal blockade and four (12.9%) had ear 
blockade. Eight (25.8%) of them had throat pain and five (16.1%) had an ulcer in the 
mouth. Five (16.1%) had nasal bleed and one (3.2%) had hoarseness as their 
presenting complaint. Eighteen (58.1%) of them had one or more swellings in the 
neck as a presenting complaint. 
Comorbidities: Six (19.4%) of them were diabetic and six (19.4%) were 
hypertensive. Eight (25.8%) has had some surgery in the past, but none with the 
history of surgery in the neck or throat. 
Performance status: The performance scale assessed with ECOG was 1 for all 
patients.  
102 
 
Anthropometric details: The mean weight and height of the patients were 60.26 ± 
12.8 kilograms and 162.06 ± 6.68 centimetres. The average BMI was 22.93± 4.48 
kilogram per square metres. There were a significant weight loss of > 10 % in two 
(6.45%) patients only. 
Radiation therapy and Chemotherapy details:  
Seven (22.6 %) of the patients received radiation therapy as adjuvant whereas for rest 
24 (77.4 %) of them the intent was radical.  
With regards to temporality, 8 (25.8%) of them sequential whereas 19 (61.3%) of the 
radiation plans were a simultaneous integrated boost. 4 (12.9%) of them had radiation 
as a single phase.  
 
12 (38.7%) patients received three cycles of neoadjuvant chemotherapy followed by 
concurrent chemoradiation therapy, whereas 15 (48.4%) of them received upfront 
chemoradiation therapy. 4 (12.9%) of them did not receive any chemotherapy.  
In total 27 (87.09%) patients received concurrent chemotherapy. 
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Fig (xv): Types of chemotherapy 
2. RESULTS OF RADIATION DOSE AND VOLUMETRIC 
CHARACTERISTICS 
 
The mean total radiation dose (TD) delivered was 67.54± 3.96 Gy. The mean 
laryngeal Dmax was 62.66 ± 11.41 Gy. The mean maximum dose received to 1cc of the 
larynx (Dmax 1cc was 53.47 ± 14.53 Gy. The mean laryngeal dose was 45.10 ± 14.14 
Gy.  
  
Fig (xvi): Mean ± standard deviation values of different dose parameters of all 
patients 
The mean volume parameters V5, V10, V15, V20, V25, V30, V35, V40, V45, 
V50,V55,V60,V65,V70 and V73.5 were 94.23%, 91.82%, 91.14%, 90.67%, 89.57%, 
86.58%, 80.56%, 71.74%, 61.12%, 46.1%, 29.33%, 11.35%, 4.23%, 0.99% and 0% 
respectively. 
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Fig (xvii): Mean ± standard deviation of the volume parameters of all patients 
 
 3.RESULTS OF LARYNGOSCOPY  ASSESSMENT 
 
All patients had normal laryngoscopy findings prior to radiation therapy.  
Midway during radiation 23 (73.2%) of them had grade 1, while 2 (6.25%) of them 
had grade 2 laryngeal oedema and 5 (16.1%) of them did not have any laryngeal 
oedema.  
At the end of radiation therapy, 23 (71.87%) of them had grade 1, whereas 6 (19.4%) 
of them had grade 2 (6.25%) laryngeal oedema and 2 (6.25%) of them did not have 
laryngeal oedema. 
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Fig (xviii): Distribution of laryngeal oedema at different time points, i.e. prior to, 
during and at end of radiation therapy 
 
4.RESULTS OF V-RQOL QUESTIONNAIRE 
 
The mean baseline V-RQOL total score was 99.27 ± 1.84. The total scores at midway 
and end of radiation therapy dropped to 82.67 ± 20.37 and 69.03 ± 19.86 respectively.  
The V-RQOL socioemotional scores prior to, midway and end of radiation therapy 
were 100 ± 0, 86.69 ± 20.07 and 76.41 ± 22.69 respectively. The physical V-RQOL 
scores prior to, midway and end of radiation therapy were 98.79 ± 3.07, 80.24 ± 21.88 
and 64.38 ± 20.35 respectively. 
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Table (II): The mean V-RQOL total and subdomain scores of all patients at different 
time points during radiation therapy 
V-RQOL score/ 
Time points 
Prior to RT Midway during RT End of RT 
Total 99.27±1.84 82.67 ±20.37 69.03 ±19.86 
Socioemotional  100 ± 0 86.69 ± 20.07 76.41 ± 22.69 
Physical 98.79 ± 3.07 80.24 ± 21.88 64.38 ± 20.35 
 
Ten (32.3%) patients had a V-RQOL total score less than 75 at midway assessment. 
But this increased to 17 (54.8%) at the end of radiation therapy.  
Eight (25.8%) had a V-RQOL socioemotional score less than 75 at midway during 
radiation therapy which increased to 15 (49.4%) at end of RT. 
 Ten (32.3%) had V-RQOL physical scores less than 75 at midway during radiation 
therapy, which increased to 26 (83.9%) at end of RT. 
 
5. CORRELATION OF RT  DOSE VOLUMETRICS AND LARYNGEAL 
EDEMA   (ASSESSED BY LARYNGOSCOPY) 
 
Two (6.5%) patients had grade≥2 oedema at midway during radiation therapy, and six 
(19.4%) had grade≥2 oedema at the end of radiation therapy. 
The mean values of DVH parameters of those patients who had grade 2 oedema 
versus grade 1 were as follows:  
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Table (III): Dose and volume parameters of patients with Laryngeal oedema grade 1 and 2 separately 
 Grade 1 Grade 2 
Laryngeal volume 12.4478 cm3 13.4908 
Dmax 6224.5 6659.7 
Dmax 1cc 5437.37 5214.19 
Dmean 4473.58 4761.15 
V5 92.68 98.27 
V10 90.15 95.50 
V15 89.43 94.74 
V20 88.94 94.17 
V25 87.6 93.65 
V30 84.37 92.88 
V35 79.85 86.20 
V40 72.82 73.62 
V45 63.16 60.93 
V50 47.59 47.99 
V55 30.6 32.09 
V60 10.06 20.08 
V65 2.71 11.47 
V70 0.96 1.43 
V73.5 0 0 
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Fig (xix): Line diagram showing the values of various volume parameters for patients who developed 
grade 1 and grade 2 laryngeal oedema separately 
There was a significant association between laryngeal oedema grades at end of RT (≤ 
1 versus >2) with V65 (p=0.028). It was found that when V65 was less than 1%, there 
was significantly less chance of grade≥ 2 oedema to occur. (Sensitivity 78.6%, 
specificity 41.2%, AUC 0.628) 
There was no association seen between laryngeal oedema and other dose-volume 
parameters at the end of radiation therapy. 
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Fig (xx): ROC curve to define the value of V65 causing grade ≥2 laryngeal oedema. 
6. CORRELATION OF RT DOSE VOLUMETRICSWITH VOICE 
RELATED QUALITY OF LIFE (ASSESSED WITH V-RQOL 
QUESTIONNAIRE) 
 
The values of different DVH parameters for those with the total V-RQOL score at end 
of radiation therapy <75(non-excellent) and >75 (excellent) were as follows:  
Table (IV): Values of dose and volume parameters for patients with a V-RQOL total 
score < 75 and >75 separately 
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 Total V-RQOL >75 Total V-RQOL <75 
Laryngeal volume 13.14 12.06 
Dmax 6337.1 6207.9 
Dmax 1cc 5472.14 5244.2 
Dmean 4353.17 4640.07 
V5 93.91 94.49 
V10 90.51 92.89 
V15 89.71 92.30 
V20 88.98 92.05 
V25 87.55 91.24 
V30 83.62 89.01 
V35 77.61 82.98 
V40 68.50 74.39 
V45 56.48 64.94 
V50 42.71 48.89 
V55 25.67 32.35 
V60 6.51 15.35 
V65 1.26 6.57 
V70 0.32 1.53 
V73.5 0 0 
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Fig (xxi):  Volume parameters for patients with V-RQOL total scores <75 and >75 separately 
 
When the V-RQOL total score of all patients are clubbed into two groups as <75 and 
>75, there was a statistically significant difference in V60, V65 and V70. The V-
RQOL score was >75 when the V60 (sensitivity 76%, specificity 36% and AUC 
0.592), V65 (sensitivity 41.2%, specificity 78.6%, AUC 0.628) and V70 (sensitivity 
17.6%, specificity 92.9%, AUC 0.553) were less than 1 %. 
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Fig (xxii): ROC curve to define the value of V65 causing the V-RQOL total score to be 
less than 75. 
 
The values of different DVH parameters for those with a socioemotional domain of V-
RQOL score at end of radiation therapy <75 (non-excellent) and >75 (excellent) were 
as follows:  
 
Table (V): Values of dose and volume parameters for patients with V-RQOL 
socioemotional scores <75 (non-excellent) and >75 (excellent) separately 
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 Socioemotional V-RQOL 
>75 (excellent) 
Socioemotional V-RQOL 
<75 (non-excellent) 
Laryngeal volume 12.76 12.32 
Dmax 6067.3 6478.4 
Dmax 1cc 5223.1 5479.4 
Dmean 4185.82 4856.82 
V5 89.47 99.31 
V10 85.84 98.20 
V15 84.80 97.89 
V20 84.10 97.65 
V25 82.84 96.74 
V30 79.42 94.21 
V35 74.16 87.38 
V40 66.20 77.65 
V45 55.47 67.15 
V50 43.06 49.34 
V55 27.17 31.63 
V60 7.60 15.35 
V65 1.14 7.52 
V70 0.28 1.14 
V73.5 0 0 
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Fig (xxiii): Volume parameters for patients with V-RQOL socioemotional scores < 75 
and >75 separately. 
For the socio-emotional domain of the V-RQOL score, the difference between groups 
with a score<75 and >75 was significant with regard to Dmean, V5, V10, V15, V20, 
V25, V30, V35, V60, V65 and V70.  
The following given are the cut off values of volume parameter for the V-RQOL 
socioemotional score to be >75 or excellent. In parentheses are the sensitivity, 
specificity and AUC respectively: 
V20 < 100% (86.7%, 43.8%, 0.656) 
V30 < 100% (86.7%, 50%, 0.679) 
V35 <26% (100%, 25%, 0.596) 
V40 <10% (100%, 25%, 0.593) 
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V50 <6% (86.7%, 31.2%, 0.562) 
V60 <3%   (53.3%, 50%, 0.39) 
V70 < 1 % (20%, 93.8%, 0.585) 
 
Fig (xxiv): ROC curve to define the value of V35 causing V-RQOL socioemotional 
score to be less than 75. 
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Fig (xxv): ROC curve to define the value of V40 causing the V-RQOL socioemotional 
score to be less than 75. 
 
The values of different DVH parameters for those with a physical domain of V-RQOL 
score at end of radiation therapy <75 (non-excellent) and >75 (excellent) were as 
follows: 
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Table (VI): Values of dose and volume parameters of patients with V-RQOL physical scores < 75 and 
> 75 separately 
 Physical V-RQOL >75 Physical V-RQOL <75 
Laryngeal volume 15.01 12.08 
Dmax 6337.1 6207.9 
Dmax 1cc 5472.14 5244.2 
Dmean 4353.17 4640.07 
V5 93.91 94.49 
V10 90.51 92.89 
V15 89.71 92.30 
V20 88.98 92.05 
V25 87.53 91.24 
V30 83.62 89.01 
V35 77.61 82.98 
V40 68.50 74.39 
V45 56.48 64.94 
V50 42.71 48.89 
V55 25.67 32.35 
V60 6.51 15.35 
V65 1.26 6.57 
V70 0.316 1.53 
V73.5 0 0 
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Fig (xxvi): Volume parameters for patients with V-RQOL physical scores <75 and >75 separately 
For the physical domain of V-RQOL score, this was significant only for V65. When 
V65 was less than 1% (sensitivity 38.5%, specificity 100%, AUC 0.715) 
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Fig (xxvii): ROC curve to define the value of V65 causing the V-RQOL physical score 
to be less than 75. 
 
When the ungrouped individual V-RQOL scores of each of the patients were 
compared against dose-volume parameters there was no significant correlation.  
 
7. CORRELATION OF   VOICE RELATED QUALITY OF LIFE  WITH LARYNGEAL EDEMA  
(ASSESSED BY LARYNGOSCOPY) 
 
Table (VII) shows the V-RQOL scores at end of radiation therapy (expressed as Mean 
± SD) for those with laryngeal oedema less than and more than Grade 2 separately 
V-RQOL scores Time point Laryngeal oedema P value 
 Grade 1 Grade 2  
V-RQOL score total Midway 83.97 ± 0.43 63.75 ± 1.77 NS 
At end 74.4 ± 17.42 46.67 ± 12.81 0.001 
V-RQOL score socioemotional Midway 87.28 ± 20.49 78.13 ±13.26 NS 
At end 82.5 ± 19.09 51.04 ± 19.53 0.001 
V-RQOL score physical Midway 81.47 ± 22.09 62.50 ± 5.90 NS 
At end 69.33 ± 18.71 43.75 ± 13.11 0.004 
 
As shown in the table, there was a significant correlation between laryngeal oedema 
and quality of life scores at the end of radiation treatment. But at midway during 
radiation therapy, there was no significant correlation between laryngeal oedema and 
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V-RQOL score groups. When the V-RQOL scores were regrouped into excellent 
versus (non-excellent) others also, significance was seen only at the end of radiation 
therapy. 
 
Fig (xxviii): Total and subdomain V-RQOL scores midway and at end of RT for 
patients with grade 1 and 2 oedema separately 
 
Table (VIII) below depicts the number of patients with grade > 2 oedema among those 
whose V-RQOL scores dropped below 75 for each domain. 
V-RQOL SCORES <75 No of patients with Laryngeal oedema 
Grades <2 Grade≥ 2 
V-RQOL score total<75 11 (64.7%) 6 (35.3%) 
V-RQOL score socioemotional <75 9 (60%) 6 (40%) 
V-RQOL score physical <75 20 (76.9%) 6 (23.1%) 
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(Percentage values given in parentheses are within a row) 
8. SUBGROUP ANALYSIS 
 
Age:  
12 (38.70%) patients were more than 50 years. Four patients (33.3%) among those 
more than 50 years had grade 2 laryngeal oedema. 19 (61.2%) patients were less than 
50 years, and two (10.52 %) of them had grade 2 laryngeal oedema. 
In the more than 50 years group, seven (58.3%) of the 12 patients had a V-RQOL 
score equal to 75, while the rest five (41.66%) had an excellent V-RQOL score at the 
end of radiation therapy. While in the < 50 years group, 17 (89.47%) of the 19 had V-
RQOL less than 75. 
The mean age of those with V-RQOL < 75 was 48.80 years versus those with an 
excellent V-RQOL had a mean age of 43.75 years. 
There was no significant difference between the quality of life or laryngeal oedema at 
end of radiation therapy between the different age groups. 
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Fig (xxix): Percentage of patients with V-RQOL Total score values <75 in age groups 
<50 and >50 separately 
 
Laryngeal volume: 
The mean laryngeal volume of all patients was 12.55 cm3.  
Those with grade 2 oedema had a mean volume of 13.49 cm3 while those with grade 1 
oedema who had smaller mean laryngeal volume 12.44 cm3. 
Those with a V-RQOL score >75 had a mean laryngeal volume of 13.14 cm3 versus 
those with <75 had 12.06 cm3. 
There was no significant difference between laryngeal oedema grades or V-RQOL 
scores with the initial volume of the larynx. 
 
Chemotherapy: 
4 (33.3%) out of 12 who underwent neoadjuvant chemotherapy had grade 2 laryngeal 
oedema, while 2 (10.53%) of the 19 who did not receive chemotherapy had laryngeal 
oedema. 
For those who did not undergo neoadjuvant chemotherapy, the total V-RQOL score at 
the end of radiation therapy was 71.18, as compared to those who underwent 
neoadjuvant chemotherapy had a lower score of 65.63. Similarly, the V-RQOL 
socioemotional and physical scores at the end of RT were 78.95 and 66.01 for those 
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who did not receive neoadjuvant chemotherapy versus lower scores of 72.40 and 
61.80 for those who did.  
 
6 (22.2%) of the 27 patients who received concurrent chemotherapy, whether upfront 
or after neoadjuvant, had grade 2 oedema, while none of the four who did not receive 
chemotherapy had grade 2 oedema. 
 
There was no significant difference between V-RQOL scores and laryngeal oedema 
grades of those who received or did not receive neoadjuvant or concurrent 
chemotherapy. 
 
Weight loss:  
Two (6.45%) had a significant weight loss of more than 10%. Both had grade 1 
laryngeal oedema at end of RT. While both patients had an excellent quality of life 
scores during the midway assessment, one of them fared poorly at the end of RT with 
a V-RQOL score of 37.5. 
There was no significant difference between laryngeal oedema grades or V-RQOL 
scores with weight loss during therapy. 
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Primary site: The primary sites were divided into groups as Nasopharynx, 
Oropharynx and others. There was no significant difference between laryngeal 
oedema grades or V-RQOL scores with different primary sites. 
 
Nodal involvement: The patients were divided into two groups N0 (no nodal 
involvement) and N+ (those with significant nodal involvement).  
 
Out of the 8 node-negative patients, 1 (3.22%) patient had grade 2 oedema and 6 
(19.35%) had grade 1 at the end of radiation therapy. Among the node-positive 
patients, 5 (16.12%) had grade 2 oedema, 24 (77.41%) had had grade 1 oedema. 
Among the node-negative patients, four (50 %) of them had V-RQOL total scores at 
the end of radiation to be less than 75, whereas this was 13 (56.5 %) out of 23 patients 
with node-positive status. 
There was no significant difference during RT and at the end between the incidence of 
laryngeal oedema or V-RQOL score groups in total, socio-emotional and physical 
domains. 
9. EFFECT OF ORAL CAVITY DOSE ON V-RQOL 
 
There was a significant difference of oral cavity Dmean and Dmax_1cc at midway during 
radiation therapy, between V-RQOL total score groups (Excellent > 75 versus others 
< 75). Similarly, a significant difference was seen for both Dmean and Dmax_1cc at 
midway between groups of the physical domain of the V-RQOL. But a significant 
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difference was seen only for Dmax_1cc at midway between groups of the socio-
emotional domain of the V-RQOL. 
 
There was no significant difference of Oral cavity Dmax, Dmean and Dmax_1cc at the end 
of radiation therapy, between V-RQOL total score groups (p= 0.682, 0.869 and 0.535 
respectively), V-RQOL physical score groups (0.113, 0.186 and 0.182 respectively) 
and socioemotional score groups (0.121, 0.250 and 0.280 respectively). 
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Discussion 
 
In IMRT for non-laryngeal head and neck cancers, various dose-volume parameters of 
radiation should be kept below a particular value for reducing the risk of laryngeal 
oedema and better voice quality. 
 
According to Sanguineti et al (39), the Dmean<43.5 Gy reduces the risk of grade 2 
laryngeal oedema. 
Fung (51) showed that mean laryngeal dose of 50 Gy received during radical RT in a 
group of patients with non-laryngeal cancers, had increased supraglottic activity, 
phase asymmetry and posterior glottic gap during video stroboscopic assessment. 
Rancati et al(64) elucidated the Dmean to the uninvolved larynx (i.e. in non-laryngeal 
cancers) to minimize the risk of laryngeal oedema has to be kept <40 to 45 Gy by 
various NTCP models. The Dmean for involved larynx has to be kept below 63 to 66 Gy 
if possible. 
LM D’Souza Lawrence et al(66) showed that Dmean to the larynx calculated as BED3 
showed a trend for correlation with laryngeal oedema. 
As per the results of the present study, the mean laryngeal dose was 45.10 ± 14.14 
Gy.  
A Dmean of 4761.15 cGy was observed among all those who had grade 2 laryngeal 
oedema, while those who received a lower Dmean dose of 4473.58 had only grade 1 
oedema.  
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JS Bae et al(65) compared the percentage of patients with laryngeal oedema with Dmax 
more than and less than a value of 68 Gy. 50% of patients aged ≤ 68 years had grade ≥ 
2 laryngeal oedema but, for > 68 years population the same was found to be 41% 
only. 
From the analysis from our study, we found out that the mean Dmax was 6266 cGy. 
The Dmax for those with grade 2 oedema was 6659.7 cGy, while the same for those 
with grade 1 laryngeal oedema was 6224.5 cGy. 
 
 
Sanguineti(39) has suggested the use of V50 < 27%, as a constraint for laryngeal 
sparing in IMRT plans as a better alternative than Dmean < 43.5 Gy. This is because it 
provides a more specific statement about the dose-volume relationship than the mean 
dose. 
The findings in the present study is that mean V55 was 32.09% in patients with grade 2 
oedema while it was 30.6% in those with grade 1. A dose-volume constraint for V55 
was not deduced by ROC curves, because the difference between groups with grade 2 
versus 1 oedema was not statistically significant. The risk of grade 2 oedema was less 
when the V65 was < 1% (sensitivity 78%, specificity 41% and AUC 62%). 
 
The mean radiation dose delivered was 72 Gy in Fung et al (69). The mean total V-
RQOL score, socioemotional score and physical score among these patients were 
80.3, 85.5 and 76.9 respectively. 
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In Vainshtein et al(44), the mean glottic dose was 33.7 Gy, and it was shown that the 
OR was 1.081; 95% CI 1.046 - 1.116 with a p < 0.001 for the mean glottic dose with 
the voice-related quality of life assessed with HNQOL-C on multivariate analysis. 
The mean radiation dose delivered in our cohort was 67.54± 3.96 Gy. The mean 
laryngeal dose among those with a V-RQOL total score <75 was 4640 cGy, while 
those with excellent quality of life with a score>75 had a lower Dmean of 4353 cGy. 
There was no statistically significant difference. The Dmean showed a similar 
difference when the V-RQOL score was stratified into two groups as <75 and >75 for 
the socioemotional (4856.8 cGy and 4185.8 cGy respectively) and the physical 
(4622.69 cGy and 3927.12 cGy respectively) domains also. 
 
Dornfield(67) showed that when Dmax was > 66 Gy to the larynx, there was a steep 
fall in the HNCI quality of life index. He assessed Dmax at various points and the ones 
significant were in the lower lateral pharyngeal wall, false cords and AE fold.  
Though a different questionnaire is used, the results are consistent with ours which 
showed that a mean Dmax of 6067.3 cGy was observed for those with a V-RQOL 
socioemotional score more than 75, while those with less than 75 had a Dmax of 6478.4 
cGy. The Dmax values for V-RQOL physical scores were 5974.4 cGy for those with a 
score of more than 75 and 6322.4 cGy for those with a score of less than 75. 
 
The only evidence in the literature for comparison of voice-related quality of life with 
dose-volume parameters in a group of patients who have exclusively received IMRT 
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was Dornfield et al(67). He compares the quality of life with dose maximum at 
various critical points, while still there is no mention of any volume parameters.  
The analysis of our data revealed that the mean percentage of the volume of larynx Vd 
receiving a particular dose, “d” (ranging from 5 Gy to 70 Gy) was less for those with a 
V-RQOL score > 75 than those with a V-RQOL score <75 for total, socio-emotional 
and physical domains. This difference between Vd for the 2 groups was significant 
only for V60, V65 and V70 for the total score, V65 alone for the physical domain and V5 
to V70 for the socio-emotional domain. 
 
In Sanguineti et al (39), univariate analysis of age with laryngeal oedema resulted in 
an odds ratio of 1.0 with 95% CI of 0.97 to 1.04, p=0.90. Bae (65) also showed that 
age was not a predictor of laryngeal oedema. 
LM D’Souza Lawrence et al (66) showed that the age directly correlated with the 
laryngeal swelling in those with laryngeal volume change from baseline above the 
second tertile i.e. more than 20.6%. 
Vainshtein et al (44) have shown the non-significance of age with the voice-related 
quality of life. 
The median age of patients in our study was 46 years. It is evident that the patients in 
our study were much younger comparatively. 
The incidence of laryngeal oedema or V-RQOL scores did not change significantly 
with age in the present study.  
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As per Lawrence D’Souza et al (66), increased laryngeal volume at planning was the 
only predictor of laryngeal oedema. Patients with baseline larger laryngeal volumes 
are less likely to show a relative volumetric change. The correlation of laryngeal 
volume with laryngeal oedema was present on multivariate analysis also confirming it 
as a strong predictor of laryngeal oedema. 
The mean laryngeal volume in our patients were 12.5538 cm3. Those with grade 2 
oedema had an average volume of 13.4908 cm3 while those with grade 1 oedema had 
a smaller mean laryngeal volume 12.4478 cm3. But there was no statistically 
significant association between laryngeal volume and laryngeal oedema or V-RQOL 
score groups. 
 
In Sanguineti et al (39), 12% of patients received chemotherapy, and the odds ratio of 
association with laryngeal oedema was 1.69 (0.76-3.77) with p=0.19. 
But J S Bae(65) et al published that only 34% of those without chemotherapy had 
significant laryngeal oedema, but those who received chemotherapy had an incidence 
of 56%. 
In our study, neither did those patients who underwent neoadjuvant chemotherapy had 
a significantly lower V-RQOL total score at the end of radiation therapy as compared 
to those who did not (71.18 versus 65.63) nor was there any significant difference in 
laryngeal oedema grades between them.  
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Sanguineti et al(39) showed that the weight loss during RT had an OR of 0.99 with 
95% CI of 0.92 to 1.07 on univariate analysis for laryngeal oedema, which was not 
significant. Our results also showed no significant correlation between weight loss 
during RT and laryngeal oedema or voice-related quality of life. 
 
Sanguineti (39) did not show any statistical difference for oropharynx site versus other 
sites. (OR 1.11; 95% CI: 0.98 to 1.26)  
Bae et al (65) showed that only 37% of those with laryngeal primary had grade 2 or 
more laryngeal oedema, but this was 57% for those with a hypopharyngeal primary. p 
value was 0.001 on univariate analysis but was not significant in multivariate analysis. 
But T classification was an independent predictor in the multivariate analysis also 
(p<0.001). 
In Fung et al (51), the non-laryngeal group had worse VHI scores as compared to 
those with the laryngeal primary. The VHI score was 25.76 versus 12.56. In 
Vainshtein et al, HNQOL-C scores of patients with a primary tumour in Tonsil versus 
base of tongue did not show any statistically significant (p=0.1804) difference. 
The patients were grouped into nasopharynx, oropharynx and others in the present 
study, and this did not yield any significant difference between them regarding 
laryngeal oedema or V-RQOL.  
 
In Sanguineti et al (39), there was an increased risk of 2.85 for N+ patients for 
laryngeal oedema (p=0.02).  
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JS Bae et al (65) had shown that there was a significant difference (p<0.001) of 
laryngeal oedema between those with N0 and N1-3 status (31% versus 63%). 
Vainshtein et al (44) showed that there was no difference in HNQOL-C scores 
between node negative and positive patients (p=0.1022) 
Contrary to what was expected, in the present study, 54.2 % of those who were node 
positive had a V-RQOL score<75, but 57.1% of those with node-negative patients had 
a score<75.  
 
Oral cavity including tongue has an important role in speech delivery, and in turn is 
intermingled when assessing the voice-related quality of life.  
Dornfield et al (67) showed that the dose to the base of tongue did not affect the 
speech-related quality of life. The p-value of the Pearson correlation coefficient 
between the doses at various points versus the speech-related quality of life was 0.41 
and 0.56 for right superior base of tongue (RSBOT) and left the superior base of 
tongue (LSBOT) respectively. 
There was no association of laryngeal oedema with oral mucositis grades 3 and 4 
versus grades 1 and 2 in Sanguineti’s study. 
The results of our study showed a good correlation of oral cavity dose with the V-
RQOL score at midway during radiation therapy. The difference between Dmax_1cc was 
significant among those with V-RQOL total, socio-emotional and physical scores <75 
(non-excellent) versus > 75 (excellent) groups, midway during RT. The Dmean 
significantly differed between only the V-RQOL total and physical scores < 75 and 
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>75 groups midway during RT. There was no correlation seen for oral cavity dose 
between groups at end of radiation therapy. 
 
Limitations 
 
(1) If a larger number of patients were included in our study, the difference in 
laryngoscopy grades and quality of life scores with differing radiation dose and 
volumes would have become probably statistically significant. 
(2) Assessment of laryngeal oedema if done with videostroboscopy would be more 
sensitive in detecting the vocal cord changes rather than the fibre-optic 
laryngoscopy. 
(3) The heterogeneity among the education of different patients from different 
sociocultural backgrounds would have had an impact on the interpretation of 
the V-RQOL questionnaire. 
Conclusion 
 
In IMRT for non-laryngeal head and neck cancers, there is a direct relationship of 
high radiation dose per volume with resultant significant laryngeal mucosal oedema. 
Any grade of laryngeal oedema (Grade ≥ 1) has an impact on the different domains of 
voice-related quality of life. 
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The different domains of V-RQOL were affected by the high radiation dose per 
volume of the larynx. 
To reduce the severity of laryngeal mucosal oedema and to improve the different 
domains of voice-related quality of life, it is good to reduce the higher radiation dose 
per volume of the larynx (≥V60 < 1%) especially in IMRT for non-laryngeal head and 
neck cancers. 
There was no significant correlation between laryngeal oedema or V-RQOL with 
different primary sites or nodal stage 
Age, laryngeal volume, different chemotherapeutic modalities, weight loss and oral 
cavity dose were not found to have any correlation with laryngeal oedema or V-
RQOL. 
 
 
 
Bibliography 
 
1.  Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer 
statistics. CA Cancer J Clin. 2011 Apr;61(2):69–90.  
2.  Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 
Jan;67(1):7–30.  
3.  Gatta G, Botta L, Sánchez MJ, Anderson LA, Pierannunzio D, Licitra L, et al. 
Prognoses and improvement for head and neck cancers diagnosed in Europe in 
135 
 
early 2000s: The EUROCARE-5 population-based study. Eur J Cancer Oxf Engl 
1990. 2015 Oct;51(15):2130–43.  
4.  Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer 
incidence and mortality worldwide: Sources, methods and major patterns in 
GLOBOCAN 2012. Int J Cancer. 136(5):E359–86.  
5.  NCRP Anual Reports... [Internet]. [cited 2016 Aug 5]. Available from: 
http://www.ncrpindia.org/Annual_Reports.aspx 
6.  Dikshit R, Gupta PC, Ramasundarahettige C, Gajalakshmi V, Aleksandrowicz L, 
Badwe R, et al. Cancer mortality in India: a nationally representative survey. The 
Lancet. 2012;379(9828):1807–1816.  
7.  Lewin F, Norell SE, Johansson H, Gustavsson P, Wennerberg J, Biörklund A, et 
al. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell 
carcinoma of the head and neck: a population-based case-referent study in 
Sweden. Cancer. 1998 Apr 1;82(7):1367–75.  
8.  Wyss AB, Hashibe M, Lee Y-CA, Chuang S-C, Muscat J, Chen C, et al. 
Smokeless Tobacco Use and the Risk of Head and Neck Cancer: Pooled Analysis 
of US Studies in the INHANCE Consortium. Am J Epidemiol. 2016 
15;184(10):703–16.  
9.  Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin 
S, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer 
Res. 1988 Jun 1;48(11):3282–7.  
10.  De Stefani E, Boffetta P, Oreggia F, Fierro L, Mendilaharsu M. Hard liquor 
drinking is associated with higher risk of cancer of the oral cavity and pharynx 
than wine drinking. A case-control study in Uruguay. Oral Oncol. 1998 
Mar;34(2):99–104.  
11.  WHO | Global status report on alcohol and health 2014 [Internet]. WHO. [cited 
2018 Jul 29]. Available from: 
http://www.who.int/substance_abuse/publications/global_alcohol_report/en/ 
12.  Chaturvedi HK, Phukan RK, Mahanta J. The Association of Selected 
Sociodemographic Factors and Differences in Patterns of Substance Use: A Pilot 
Study in Selected Areas of Northeast India. Subst Use Misuse. 2003 Jan 
1;38(9):1305–22.  
13.  Pal H, Srivastava A, Dwivedi SN, Pandey A, Nathe J. Prevalence of Drug Abuse 
in India through a National Household Survey.  
14.  Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, et al. 
Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, 
and the risk of head and neck cancer: pooled analysis in the International Head 
136 
 
and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst. 2007 May 
16;99(10):777–89.  
15.  Guha N, Warnakulasuriya S, Vlaanderen J, Straif K. Betel quid chewing and the 
risk of oral and oropharyngeal cancers: a meta-analysis with implications for 
cancer control. Int J Cancer. 2014 Sep 15;135(6):1433–43.  
16.  Raghupathy R, Hui EP, Chan ATC. Epstein-Barr virus as a paradigm in 
nasopharyngeal cancer: from lab to clinic. Am Soc Clin Oncol Educ Book Am 
Soc Clin Oncol Meet. 2014;149–53.  
17.  Hsu W-L, Chen J-Y, Chien Y-C, Liu M-Y, You S-L, Hsu M-M, et al. 
Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: 
a 20-year follow-up study on 9,622 males without family history in Taiwan. 
Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am 
Soc Prev Oncol. 2009 Apr;18(4):1218–26.  
18.  Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct 
risk factor profiles for human papillomavirus type 16-positive and human 
papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008 
Mar 19;100(6):407–20.  
19.  Tongue and tonsil carcinoma - Shiboski - 2005 - Cancer - Wiley Online Library 
[Internet]. [cited 2018 Jul 29]. Available from: 
https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.20998 
20.  Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M. HPV in 
oropharyngeal cancer: the basics to know in clinical practice. Acta 
Otorhinolaryngol Ital. 2014;34(5):299.  
21.  Stephen JK, Divine G, Chen KM, Chitale D, Havard S, Worsham MJ. 
Significance of p16 in Site-specific HPV Positive and HPV Negative Head and 
Neck Squamous Cell Carcinoma. Cancer Clin Oncol. 2013;2(1):51–61.  
22.  Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, et al. HPV 
DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a 
systematic review and meta-analysis. Lancet Oncol. 2014 Nov;15(12):1319–31.  
23.  Bunn BK, Van Heerden WFP. HIV/AIDS-associated malignancies of the head 
and neck: a clinical review. South Afr Dent J. 2012;67(10):590–592.  
24.  Purgina B, Pantanowitz L, Seethala RR. A Review of Carcinomas Arising in the 
Head and Neck Region in HIV-Positive Patients. Pathol Res Int. 2011;2011:1–
12.  
25.  Sale KA, Wallace DI, Girod DA, Tsue TT. Radiation-induced malignancy of the 
head and neck. Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head 
Neck Surg. 2004 Nov;131(5):643–5.  
137 
 
26.  Richardson DB, Cardis E, Daniels RD, Gillies M, O’Hagan JA, Hamra GB, et al. 
Risk of cancer from occupational exposure to ionising radiation: a retrospective 
cohort study of workers in France, the United Kingdom, and the United States 
(INWORKS). The BMJ [Internet]. 2015 Oct 20;351. Available from: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612459/ 
27.  Farrow DC, Vaughan TL, Berwick M, Lynch CF, Swanson GM, Lyon JL. Diet 
and nasopharyngeal cancer in a low-risk population. Int J Cancer. 1998 Dec 
9;78(6):675–9.  
28.  Birkeland AC, Auerbach AD, Sanborn E, Parashar B, Kuhel WI, 
Chandrasekharappa SC, et al. Postoperative clinical radiosensitivity in patients 
with Fanconi anaemia and head and neck squamous cell carcinoma. Arch 
Otolaryngol Head Neck Surg. 2011 Sep;137(9):930–4.  
29.  Kutler DI, Auerbach AD, Satagopan J, Giampietro PF, Batish SD, Huvos AG, et 
al. High Incidence of Head and Neck Squamous Cell Carcinoma in Patients With 
Fanconi Anemia. Arch Otolaryngol Neck Surg. 2003 Jan 1;129(1):106.  
30.  Rosenberg PS, Alter BP, Ebell W. Cancer risks in Fanconi anemia: findings from 
the German Fanconi Anemia Registry. Haematologica. 2008 Apr;93(4):511–7.  
31.  Lewis-Jones H, Colley S, Gibson D. Imaging in head and neck cancer: United 
Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016 
May;130(Suppl 2):S28–31.  
32.  Recommendations for cross-sectional imaging in cancer management, Second 
edition: Head and neck cancers. :20.  
33.  Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, 
et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a 
bridge from a population-based to a more “personalized” approach to cancer 
staging. CA Cancer J Clin. 2017 Mar 1;67(2):93–9.  
34.  Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis 
of 17 cases. Cancer. 1976 Mar;37(3):1571–6.  
35.  Vokes EE. Induction Chemotherapy for Head and Neck Cancer: Recent Data. 
The Oncologist. 2010 Oct 1;15(Supplement 3):3–7.  
36.  Cho B. Intensity-modulated radiation therapy: a review with a physics 
perspective. Radiat Oncol J. 2018 Mar;36(1):1–10.  
37.  Taylor A, Powell MEB. Intensity-modulated radiotherapy—what is it? Cancer 
Imaging. 2004 Mar 26;4(2):68–73.  
38.  Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. 
Parotid-sparing intensity modulated versus conventional radiotherapy in head and 
138 
 
neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. 
Lancet Oncol. 2011 Feb;12(2):127–36.  
39.  Sanguineti G, Adapala P, Endres EJ, Brack C, Fiorino C, Sormani MP, et al. 
Dosimetric predictors of laryngeal edema. Int J Radiat Oncol Biol Phys. 2007 Jul 
1;68(3):741–9.  
40.  Eisbruch A, Schwartz M, Rasch C, Vineberg K, Damen E, Van As CJ, et al. 
Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: 
which anatomic structures are affected and can they be spared by IMRT? Int J 
Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425–39.  
41.  Nguyen NP, Vock J, Chi A, Ewell L, Vos P, Mills M, et al. Effectiveness of 
intensity-modulated and image-guided radiotherapy to spare the mandible from 
excessive radiation. Oral Oncol. 2012 Jul;48(7):653–7.  
42.  Theunissen EA, Zuur CL, Yurda ML, van der Baan S, Kornman AF, de Boer JP, 
et al. Cochlear sparing effects of intensity modulated radiation therapy in head 
and neck cancers patients: a long-term follow-up study. J Otolaryngol - Head 
Neck Surg. 2014 Aug 6;43(1):30.  
43.  Rancati T, Schwarz M, Allen AM, Feng F, Popovtzer A, Mittal B, et al. 
Radiation Dose-Volume Effects in the Larynx and Pharynx. Int J Radiat Oncol 
Biol Phys. 2010 Mar 1;76(3 Suppl): S64–9.  
44.  Vainshtein JM, Griffith KA, Feng FY, Vineberg KA, Chepeha DB, Eisbruch A. 
Patient-reported voice and speech outcomes after whole-neck intensity modulated 
radiation therapy and chemotherapy for oropharyngeal cancer: prospective 
longitudinal study. Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):973–80.  
45.  Freedman L. A radiation oncologist’s guide to contouring the larynx. Pract 
Radiat Oncol. 2016 Mar 1;6(2):129–30.  
46.  Choi M, Refaat T, Lester MS, Bacchus I, Rademaker AW, Mittal BB. 
Development of a standardized method for contouring the larynx and its 
substructures. Radiat Oncol. 2014;9:285.  
47.  Brouwer CL, Steenbakkers RJHM, Bourhis J, Budach W, Grau C, Grégoire V, et 
al. CT-based delineation of organs at risk in the head and neck region: 
DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG 
Oncology and TROG consensus guidelines. Radiother Oncol. 2015 Oct 
1;117(1):83–90.  
48.  Christianen MEMC, Langendijk JA, Westerlaan HE, van de Water TA, Bijl HP. 
Delineation of organs at risk involved in swallowing for radiotherapy treatment 
planning. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2011 Dec;101(3):394–
402.  
139 
 
49.  RTOG/EORTC Late Radiation Morbidity Scoring Schema [Internet]. [cited 2018 
Apr 27]. Available from: 
https://www.rtog.org/ResearchAssociates/AdverseEventReporting/RTOGEORT
CLateRadiationMorbidityScoringSchema.aspx 
50.  Common Terminology Criteria for Adverse Events (CTCAE) | Protocol 
Development | CTEP [Internet]. [cited 2018 Apr 29]. Available from: 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc
_50 
51.  Fung K, Yoo J, Leeper HA, Hawkins S, Heeneman H, Doyle PC, et al. Vocal 
function following radiation for non-laryngeal versus laryngeal tumours of the 
head and neck. The Laryngoscope. 2001 Nov;111(11 Pt 1):1920–4.  
52.  Honocodeevar-Boltežar I, Žargi M. Voice Quality After Radiation Therapy for 
Early Glottic Cancer. Arch Otolaryngol Neck Surg. 2000 Sep 1;126(9):1097–
100.  
53.  Bless DM, Hirano M, Feder RJ. Videostroboscopic evaluation of the larynx. Ear 
Nose Throat J. 1987 Jul;66(7):289–96.  
54.  Focht KL, Martin-Harris B, Bonilha HS. Stroboscopic Parameters Reported as 
Voice Outcome Measures in Patients Treated for Laryngeal Cancer: A 
Systematic Review. J Med Speech-Lang Pathol [Internet]. 2013 Sep;21(3). 
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203318/ 
55.  Marciscano AE, Charu V, Starmer HM, Best SR, Quon H, Hillel AT, et al. 
Evaluating Post-Radiotherapy Laryngeal Function with Laryngeal 
Videostroboscopy in Early Stage Glottic Cancer. Front Oncol [Internet]. 2017 
Jun 12;7. Available from: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467001/ 
56.  Lazarus CL. Effects of chemoradiotherapy on voice and swallowing. Curr Opin 
Otolaryngol Head Neck Surg. 2009 Jun;17(3):172–8.  
57.  Carrara-de Angelis E, Feher O, Barros APB, Nishimoto IN, Kowalski LP. Voice 
and swallowing in patients enrolled in a larynx preservation trial. Arch 
Otolaryngol Head Neck Surg. 2003 Jul;129(7):733–8.  
58.  Jacobi I, van der Molen L, Huiskens H, van Rossum MA, Hilgers FJM. Voice 
and speech outcomes of chemoradiation for advanced head and neck cancer: a 
systematic review. Eur Arch Otorhinolaryngol. 2010 Oct;267(10):1495–505.  
59.  Cohen JT, Safadi A, Fliss DM, Gil Z, Horowitz G. Reliability of a Transnasal 
Flexible Fiberoptic In-Office Laryngeal Biopsy. JAMA Otolaryngol Neck Surg. 
2013 Apr 1;139(4):341–5.  
140 
 
60.  Ringash J, Bezjak A. A structured review of quality of life instruments for head 
and neck cancer patients. Head Neck. 2001 Mar;23(3):201–13.  
61.  Ojo B, Genden EM, Teng MS, Milbury K, Misiukiewicz KJ, Badr H. A 
systematic review of head and neck cancer quality of life assessment instruments. 
Oral Oncol. 2012 Oct;48(10):923–37.  
62.  Hogikyan ND, Sethuraman G. Validation of an instrument to measure the voice-
related quality of life (V-RQOL). J Voice. 1999;13(4):557–569.  
63.  Deshpande MS, Kakade AC, Chaukar DA, Gore VT, Pai PS, Chaturvedi P, et al. 
Validation and assessment of the voice-related quality of life in Indian patients 
undergoing total laryngectomy and primary tracheoesophageal puncture. Head 
Neck. 2009 Jan;31(1):37–44.  
64.  Rancati T, Fiorino C, Sanguineti G. NTCP Modeling of Subacute/Late Laryngeal 
Edema Scored by Fiberoptic Examination. Int J Radiat Oncol. 2009 Nov 
1;75(3):915–23.  
65.  Bae JS, Roh J-L, Lee S, Kim S-B, Kim JS, Lee JH, et al. Laryngeal oedema after 
radiotherapy in patients with squamous cell carcinomas of the larynx and 
hypopharynx. Oral Oncol. 2012 Sep;48(9):853–8.  
66.  Souza-Lawrence LM de, Ricchetti F, Wu B, McNutt T, Sanguineti G. Predictors 
of Laryngeal Edema during IMRT for Head and Neck Cancer. Int J Radiat Oncol 
• Biol • Phys. 2010 Nov 1;78(3):S469.  
67.  Dornfeld K, Simmons JR, Karnell L, Karnell M, Funk G, Yao M, et al. Radiation 
doses to structures within and adjacent to the larynx are correlated with long-term 
diet- and speech-related quality of life. Int J Radiat Oncol Biol Phys. 2007 Jul 
1;68(3):750–7.  
68.  Ma Y, Green R, McCabe D, Goldberg L, Woo P. Long-term Voice Outcome 
Following Radiation Versus Laser Microsurgery in Early Glottic Cancer. J Voice 
[Internet]. 2017 Dec 8; Available from: 
http://www.sciencedirect.com/science/article/pii/S0892199717303260 
69.  Fung K, Lyden TH, Lee J, Urba SG, Worden F, Eisbruch A, et al. Voice and 
swallowing outcomes of an organ-preservation trial for advanced laryngeal 
cancer. Int J Radiat Oncol. 2005 Dec;63(5):1395–9.  
70.  Oridate N, Homma A, Suzuki S, Nakamaru Y, Suzuki F, Hatakeyama H, et al. 
Voice-Related Quality of Life After Treatment of Laryngeal Cancer. Arch 
Otolaryngol Neck Surg. 2009 Apr 1;135(4):363–8.  
71.  Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With 
Oropharyngeal Cancer - Full Text View - ClinicalTrials.gov [Internet]. [cited 
2018 Jul 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT01302834 
141 
 
72.  Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology 
Group (RTOG) and the European organization for research and treatment of 
cancer (EORTC). Int J Radiat Oncol. 1995 Mar 30;31(5):1341–6.  
142 
 
Appendix-I (Institutional Ethical & Research Board approval 
letter)
143 
 
144 
 
145 
 
 
Appendix-II 
146 
 
Appendix- II (Clinical Performa for data collection) 
 
Name:      Hosp.No.   R.T. No. 
Age :      DOB:     Sex: 
Address. 
 Local     Permanent 
 Ph no     Ph no 
Socioeconomic status:   1. Patient’s Occupation : 
   2. Patient’s Education   : 
Presenting complaints: 
     Y/N   Duration 
Throat  pain            
Dysphagia(liquids/semisolids/solids)     
Hoarseness       
Cough        
Stridor   
Neck swelling:       
Headache :      
Others:   
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Addictions: 
1.  Smoking  Y/N Number per day-    Duration -      /yrs      2. 
Smokless Tobacco       Y/N              Duration -      /yrs       
 Type:   
3. Alcohol     Y/N          Amount & frequency -    Duration -       /yrs      
Associated diseases:   Premalignant conditions               
     DM/ HT/ TB/ Others 
    Allergies  
Past history:   Previous malignancies 
    Surgeries  
    major illness  
Drug history: 
Treatment History:    Surgery(Elsewhere/ At CMCH)- 
     Radiotherapy(Elsewhere/ At CMCH)- 
     Chemotherapy(Elsewhere/ At CMCH)- 
Family history- 
GENERAL EXAMINATIONS: 
Performance status: ECOG  
Physical parameters :Weight-  Height-      BSA- 
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Vitals   :BP-        PR- 
Pallor/ Icterus/ Edema 
Stridor / Tracheostomy / Ryles tube 
Systemic examination:         CVS 
    RS 
    Abdomen 
Local examination:       
NPL scopy /IDL Sopy   
Neck-  
Lymphnodes-Y/N 
Side Level no Size 
Mobile/ 
Fixed 
Discrete/ 
Matted 
Skin –Free/ 
Tethered 
Ulcerated 
right 
1      
2      
3      
4      
5      
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left 
1      
2      
3      
4      
5      
Clinical Diagnosis: 
Site:     T         N         M                   Stage: 
INVESTIGATIONS 
Haemogram ( date:           ) HB-   PCV-  MCV-      
    TC-  DC  -  Platelets- 
Biochemistry  ( date:           ) Creatinine-   Creatinine clearance – 
    LFT- 
    Na -  K -  Ca -  Mg –  
Virology        ( date:            )  HIV-  HCV-  HbsAg- 
Chest xray     ( date:            ) - 
Ultrasonogram ( date:          )  - 
Barium swallow ( date:       ) - 
Upper GI Scopy ( date:        ) – 
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CT scan ( date:           ) - 
Histopathology Biopsy No (                /         )-  Specimen No(           /    
)-( date:            )         Squamous cell carcinoma / others –  
   Well / Moderately / poorly differentiated 
   Margins –  
   Lymphnodes: No-            extracapsular invasion: Y/N 
   Lymphatic / vascular invasion - Y/N 
FNAC:    Site -     Report - 
 ( date:            )    
Final diagnosis 
Site     T  N  M    Stage           
Sub Site 
TREATMENT DETAILS : CONVENTIONAL 
EXTERNAL RT-    Preoperative/  Post-operative/  Radical/  Palliative. 
Overall treatment time: 
Date started: 
Date completed: 
Machine:Co 60 / 6X / 15X. 
Dose 
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Site primary +ve Nodes Prophylactic nodes Lower neck Posterior neck 
Dose      
 
Fractions / week: 
Technique: 
TD / # 
Treatment Break  Yes/No    
No of breaks Duration  in days Reason 
1   
2   
3   
4   
Field size 
SAD/SSD 
Spine shielding-  Y/N    At ---------Gy 
Separation at  three level: 1-         2-             3-             Calculation done for------
separation 
Posterior Neck Electron energy: Rt -                            Lt- 
BRACHYTHERAPY: 
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Dose : 
Dose Rate: HDR / LDR 
Technique: 
No of weeks after EBRT:  
 
Appendix III (V-RQOL Questionnaire) 
 
VOICE RELATED QUALITY OF LIFE (V-RQOL) MEASURE 
 
Name _________________________________________  
Date _________________________________ 
We are trying to learn more about how a voice problem can affect your day-to-day 
activities. On this paper you will find a list of voice related problems. Please answer 
all questions based upon what your voice was like over the past 2 weeks. There are no 
right or wrong answers. 
Considering both how severe the problem is when you get it, and how frequently it 
happens, please rate each item below on how bad it is. (i.e. the amount of each 
problem that you have). Use the following scale to rate the amount of problem you 
have. 
1= none, not a problem 
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2= a small amount 
3= a moderate (medium) amount 
4= a lot 
5= Problem is “as bad as it can be” 
 
Because of my voice, how much of a problem is this? 
1. I have trouble speaking loudly or being heard in noisy situations 1  2    3      4        5 
2. I run out of air and need to take frequent breaths while talking   1   2     3     4        5 
3. I sometimes do not know what will come out when I begin speaking 
       1   2     3      4        5 
4. I am sometimes anxious or frustrated because of my voice        1   2     3       4        5 
5. I sometimes get depressed because of my voice         1   2     3      4        5 
6. I have trouble using the telephone (because of my voice)       1   2     3       4        5 
7. I have trouble doing my job or practising my profession(because of my voice) 
1    2       3       4          5 
8. I avoid going out usually (because of my voice)  1   2     3       4        5 
9. I have to repeat myself to be understood   1   2     3       4        5 
10. I have become less outgoing  (because of my voice) 1   2     3       4        5 
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Appendix-IV (V-RQOL scoring methods) 
Scoring  
 
- # items) 
Domain (Items 4, 5, 8, 10)0 - (Raw Score - 4) × 100) 
Appendix V (RTOG grading of laryngeal oedema) 
 
RTOG Grade Description 
0 No oedema 
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1 Slight oedema = ‘‘minimal’’ thickening of the epiglottis, 
aryepiglottic folds, arytenoids, and false cords 
2 Moderate oedema = more diffuse and evident oedema, although 
still without significant or symptomatic airway obstruction 
3 Severe oedema = Significant airway obstruction 
4 Necrosis 
 
Appendix VI (Informed consent) 
 
INFORMATION SHEET 
Study title: Effect of Radiation Dose and Volume to the Larynx in Intensity 
Modulated Radiation Therapy of non-laryngeal head and neck malignancies. 
The head and neck cancers account for one-third of cancers in the country. According to the 
Indian Council of Medical Research (ICMR), 0.2 to 0.25 million patients are diagnosed each 
year with head and neck cancers. The main modalities of treatment for the cure of head and 
neck cancers include surgery, radiation therapy and/or chemotherapy. 
 
The radiation therapy of head and neck cancers result in many quality of life issues related to 
skin reactions, mucositis, dryness of mouth, difficulty in swallowing, speech and voice issues. 
This is because radiation dose required for tumour control would cause acute and late normal 
tissue effects, thus worsening the quality of life of the patient. Intensity-modulated radiation 
therapy (IMRT) has a definite advantage in this setting. IMRT is based on computer-
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optimized treatment planning and a computer-controlled treatment delivery system. This 
generates dose distributions that sharply conform to the tumour target while minimizing the 
dose delivered to the surrounding normal tissues. The simultaneous integrated boost (SIB) 
treatment would offer an additional radiobiological advantage in terms of lower dose per 
fraction to the normal tissues while delivering high dose per fraction to the target volume. In 
head and neck cancers, treatment can be accurately delivered with IMRT because it results in 
relative sparing of normal structures such as parotid glands, and also organ motion is virtually 
absent with proper immobilization. 
This study aims at assessing the effects of IMRT on larynx in patients with cancers of the 
Head and neck other than the larynx. It also assesses the quality of life in patients undergoing 
radiation therapy for head and neck malignancies through a questionnaire. 
You are being requested to participate in this study assessing the effects of radiation on 
larynx in IMRT and the quality of life issues. 
If you take part what you will have to do? 
You will have to undergo assessment by laryngoscopy prior to, midway and after completion 
of the radiation treatment. You will have to answer a questionnaire enquiring issues you face 
during radiation treatment at three of your visits- one before starting radiation treatment, one 
midway and one after the end of radiation treatment. The laryngoscopy done midway during 
the radiation treatment would be performed as an additional procedure to see the status of 
your voice box in between the treatment. 
Can you withdraw from the study after it starts? 
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Yes. Your participation in the study is absolutely voluntary. If you withdraw from the 
study during the treatment, it will not affect your treatment in any way. 
What are the benefits of this study? 
The results of dose and volume constraints which should be maintained to reduce the 
toxicity to the larynx during radiation therapy, obtained from this study can be applied 
for treating patients with Head and neck malignancies in future. This would help to 
reduce the voice and speech problems to the patients taking radiation therapy to Head 
and neck. 
Will your personal details be kept confidential? 
Yes. The results of the study, when published in any journal, would not reveal your 
name or personal information in any form. 
Will you have to bear any extra expenses because of your participation in this 
study? 
No. The laryngoscopy procedure which is done midway during the radiation therapy 
is covered by the study fund. You will not have to pay for it. 
For any further queries, you may please contact: (Address and phone number 
was provided) 
Informed Consent form to participate in a research study  
Study Title: Effect of Radiation Dose and Volume to the Larynx in Intensity Modulated 
Radiation Therapy of non-laryngeal head and neck malignancies. 
Study Number: ____________ 
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Subject’s Initials: __________________  
Subject’s Name: _________________________________________ 
Date of Birth / Age: ___________________________ 
 
(i)  I confirm that I have read and understood the information sheet dated 
____________ for the above study and have had the opportunity to ask 
questions. [  ] 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected. [  ] 
(iii)  I understand that the Ethics Committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree with this access. However, I understand that 
my identity will not be revealed in any information released to third parties or 
published. [  ] 
(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for the scientific purpose(s). [  ] 
(v)  I agree to take part in the above study. [  ] 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
Date: _____/_____/______ 
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Signatory’s Name: _________________________________         Signature:  
Representative: _________________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
Signature of the Investigator: _______________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
Signature or thumb impression of the Witness: ___________________________ 
Date: _____/_____/_______ 
Name & Address of the Witness: ______________________________ 
 
 
Appendix- VII (Master sheet) 
 
Key for master sheet: 
Gender: 1 – male, 2 – female 
Ethnicity: 1- North East Indian 2- North Indian 3-South Indian 4 –Others 
Smoking: 1-nil 2-yes 
Alcohol: 1-nil 2-yes 
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Chewing tobacco: 1-nil 2-yes 
Primary site: 1- Nasopharynx 2- sinonasal malignancy 3- oropharynx 4- oral cavity 5- 
olfactory neuroblastoma 6- maxilla 9-others 
Histology: 1-Well differentiated squamous carcinoma 2-Moderately differentiated 
squamous carcinoma 3- Poorly differentiated squamous carcinoma  4- Poorly 
differentiated malignancy 5-Sinonasal adenocarcinoma 6- Adenocarcinoma 7-
Neuroendocrine carcinoma 8- Undifferentiated 9-Adenoid cystic carcinoma 10- 
Others 
T: 1-1, 2-2, 3-3, 4-4a, 5-4b 
N: 1-1, 2-2a, 3-2b, 4-2c, 5-3 
Stage: I-1, II-2, III-3, IVA-4, IVB-5 
Hoarseness, Dysphagia, Nasal block, Ear block, Nasal bleed, Throat pain, Ulcer 
mouth, Neck swelling: 1-nil 2-yes 
Diabetes, Hypertension, Surgeries: 1-nil 2-yes 
ECOG performance status: 0-1, 1-2, 2-3, 3-4, 4-5  
Pallor: 1-nil 2-yes 
RT: 1- Postoperative, 2-Radical 
Chemotherapy: 1-nil, 2 -Neoadjuvant, 3 -concurrent, 4- Neoadjuvant and concurrent 
chemoradiation therapy 
Boost temporality: 1-SIB, 2-Sequential, 3- Single phase 
RT dose: in centigray 
No of fractions: Total number of fractions 
dpf: Dose per fraction in cGy  
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Oedema grade: Baseline, midway and at End: 0-grade 0, 1- grade 1, 2- grade 2, 3-
grade 3, and 4-grade 4 
Laryngeal volume: reported in cubic centimetres (cc) 
Dmax: Maximum laryngeal dose to any point in the laryngeal volume reported in 
Centigray (cGy). 
Dmax (1cc): Maximum laryngeal dose to any 1 cc of the laryngeal volume reported in 
Centigray (cGy). 
Dmean: Mean laryngeal dose reported in Centigray (cGy).  
Vd: Percentage of the volume of the larynx receiving a particular dose, d. 
 
